








































Funding	 for	 this	 research	was	 received	 from	 grants	 funded	 by	 the	Ministry	 of	
Education	and	Microbiology	Department	Vaccine	 Initiative	awarded	 to	Dr	Seah	
Geok	 Teng	 (2006	 –	 08),	 and	 from	 the	 National	 Research	 Foundation	 (2008	 –	
2011)	 under	 the	 auspices	 of	 the	 Singapore‐MIT	 Alliance	 for	 Research	 and	
Technology	 (SMART)	 Infectious	 Disease	 Interdisciplinary	 Research	 Group	 (ID‐
IRG)	 where	 Dr	 Seah	 Geok	 Teng	 and	 the	 late	 Professor	 David	 B	 Schauer	 were	
investigators.	My	graduate	studies	were	financed	by	a	scholarship	funded	by	the	




not	have	been	possible	 if	not	 for	 the	many	people	who	have	so	selflessly	given	
me	sound	guidance,	strong	support	and	immense	encouragement	along	the	way.	
I	owe	my	deepest	gratitude	to	my	supervisor	and	mentor,	Dr	Seah	Geok	Teng,	for	
her	 invaluable	guidance	and	advice,	her	 strong	 support	 in	 times	of	uncertainty	
and	 when	 I	 was	 far	 away	 in	 a	 foreign	 land,	 and	 especially	 for	 devoting	 her	
precious	time	to	my	project	amidst	her	multiple	roles	as	an	adjunct	professor,	a	
practicing	doctor	and	a	new	mother,	in	the	last	leg	of	my	PhD.	I	also	extend	my	






Mien,	Megan,	 Puk,	Adrienne,	Katie	 and	Alex,	who	have	 given	me	much	needed	
support,	especially	on	bad	experimental	days,	and	kept	me	sane	at	one	point	or	
another	 through	 the	 course	of	my	PhD.	My	special	 thanks	 also	 to	Mr	YN	Chan,	
Mrs	KT	Thong,	Arek	 and	 Siew	Chin	 for	 their	 technical	 help	with	managing	 the	
equipment	needed	 for	 this	project,	 including	 the	 flow	cytometers	and	Luminex	
machine.	 I	 feel	 indebted	 to	my	many	 colleagues	 in	 the	 SGT	 lab	 at	 NUS,	 in	 the	
Schauer	lab	at	MIT,	as	well	as	in	SMART,	particularly	Carmen,	Joanne,	Wei	Xing,	
Arek,	 Isadora,	 Siew	Chin,	Hooi	 Linn,	Maggie,	Da	Hai,	 Lena,	 Yie	Hou,	 Lan	Hiong,	











Human	 epidemiological	 studies	 suggest	 that	 poor	 efficacy	 of	 the	 tuberculosis	
(TB)	 vaccine,	 Mycobacterium	 bovis	 bacille	 Calmette‐	 Guérin	 (BCG),	 may	 be	
because	 of	 immuno‐modulatory	 effects	 of	 exposure	 to	 environmental	






Heat‐killed	CHE	 intra‐peritoneal	sensitisation	 induced	CD4+	T	cells	which	 lysed	
BCG‐infected	 macrophages	 in	 vitro.	 The	 cytotoxicity	 was	 dependent	 on	 IFN‐,	
perforin	 and	 FasL.	 Sensitisation	 with	 an	 unrelated	 bacterium	 failed	 to	 induce	
cytotoxicity,	 therefore	priming	of	T	cells	 cross‐reactive	with	BCG,	and	not	non‐





to	 naïve	 mice,	 after	 BCG	 lung	 challenge.	 Although	 the	 frequency	 of	 systemic	
CD4+CD25+	cells	was	unremarkable	after	CHE	sensitisation,	adoptive	transfer	of	
these	 Tregs	 to	 naïve	 mice	 followed	 by	 BCG	 challenge	 led	 to	 reduced	 lung	
lymphocyte	 recruitment,	 reduced	 lung	 IL‐2	 and	 increased	 systemic	 IL‐10	
	 iv
production.	 This	 suggests	 functional	 suppression	 of	 local	 BCG	 responses	 by	
CD4+CD25+	Tregs	from	CHE‐sensitised	mice.		
	
Memory	 responses	 after	 transient	 CHE	 lung	 colonisation	 led	 to	 increases	 in	
Tregs	weeks	after	no	 live	CHE	was	recoverable.	Different	doses	of	 inhaled	CHE	
exposure	 were	 tested	 –	 higher	 doses	 induced	 stronger	 Treg	 responses	 and	
weaker	 BCG‐specific	 IFN‐γ	 responses.	 Subsequent	 experiments	 used	 repeated	
low	dose	 live	intra‐tracheal	CHE	exposure	to	mimic	natural	human	inhalational	
exposure,	 followed	 by	 subcutaneous	 BCG	 vaccination.	 Systemic	 IL‐10,	 mainly	
produced	 by	 CD4+CD25‐FoxP3+	 inducible	 Tregs,	 was	 increased	 and	 associated	
with	 reduced	 frequency	 of	 IFN‐γ	 producing	 memory	 cells	 recognising	 a	 BCG‐
specific	 epitope.	 Thus,	 adaptive	 Tregs	 also	 have	 a	 role	 in	 suppressing	 BCG‐
specific	inflammation	in	CHE‐sensitised	mice.		
	
To	 explore	 if	 post‐BCG	 CHE	 exposure	 had	 similar	 effects,	 BCG	 vaccination	 of	
weanling	 mice	 was	 followed	 by	 low	 dose	 CHE	 intra‐tracheal	 exposures.	 This	
mainly	 induced	 natural	 Tregs,	 with	 minimal	 IL‐10	 induction.	 Suppression	 of	
inflammatory	 cell	 recruitment	 in	 the	 lungs	 to	 subsequent	 BCG	 lung	 challenge	
was	 noted,	 associated	 with	 reduced	 lung	 chemokines,	 in	 spite	 of	 elevated	
systemic	IFN‐γ	responses.	The	rate	of	inflammatory	cell	recruitment	to	the	lung	
early	 in	 TB	 infection	 is	 increasingly	 recognised	 as	 the	 critical	 determinant	 of	




These	 two	mechanisms	 proposed	 for	 effects	 of	 CHE	 exposure	 on	 BCG‐induced	
immunity	 are	 novel.	 This	 work	 is	 also	 the	 first	 to	 provide	 a	 mechanistic	
explanation	for	how	Env	exposure	modulates	an	existing	BCG	vaccine	response.	
This	 accounts	 for	 observations	 of	 lack	 of	 BCG‐induced	 protection	 in	 humans	
living	 in	 Env‐prevalent	 areas,	 and	 suggests	 how	 prospective	 candidate	 TB	
vaccines	 could	 be	 screened	 to	 avoid	 problems	 of	 BCG	 vaccine.	 It	 also	 explains	
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1) Peiying,	 Ho,	 Megan	 McBee,	 Geok	 Teng	 Seah	 and	 David	 Schauer.	 M.	
chelonae	 exposure	 post‐BCG	 vaccination	 suppresses	 BCG‐specific	
responses.	 Poster	 presentation.	 International	 Congress	 of	 Mucosal	
Immunology,	July	2009,	Boston,	USA.		
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2) Effects	 of	 environmental	 mycobacteria	 post‐BCG	 vaccination.	 Oral	




Geok	 Teng	 Seah.	 Mycobacterium	 chelonae	 sensitisation	 prior	 to	 BCG	
vaccination	 induces	 regulatory	 T	 cells	 that	 suppress	 IFN‐	 responses.	






















































































































































































































































































Ab	 	 	 Antibody	
BAL	 	 	 Bronchoalveolar	lavage		
BCG	 	 	 bacille	Calmette‐Guérin	
BSA	 	 	 Bovine	serum	albumin	
CHE	 	 	 Mycobacterium	chelonae	
CTL	 	 	 Cytolytic	T	lymphocyte	
DC	 	 	 Dendritic	cell	
DDAO‐SE	 	 		dodecyldimethylamine	oxide‐succinimidyl	ester	
DOTS	 	 	 		Directly	observed	treatment,	short‐course	
DTH	 	 	 		Delayed	type	hypersensitivity	
ELISA	 	 	 Enzyme‐linked	immunosorbent	assay	
ELISpot	 	 Enzyme‐linked	immunospot	assay	
Env	 	 	 Environmental	mycobacteria	
FAC	 	 	 Ferric	ammonium	citrate	supplement	
FBS	 	 	 Foetal	bovine	serum	
FoxP3	 	 	 Forkhead‐box	P3	
HBSS	 	 	 Hank’s	balanced	salt	solution	
HIV	 	 	 Human	immunodeficiency	virus	
IFN‐	 	 	 Interferon	gamma	
IL	 	 	 Interleukin		
i.p.	 	 	 Intra‐peritoneal	
i.n.	 	 	 Intra‐nasal	
	 xix
i.t.	 	 	 Intra‐tracheal	
iTreg	 	 	 Inducible	(or	adaptive)	regulatory	T	cell	
mAb	 	 	 Monoclonal	antibody	
MHC	 	 	 Major	histocompatibility	complex	
Mtb	 	 	 Mycobacterium	tuberculosis	
NK	 	 	 Natural	killer	cell	
nTreg	 	 	 Natural	regulatory	T	cell	
OADC	 	 	 Oleic	acid‐albumin‐dextrose‐catalase	enrichment	
PBS	 	 	 Phosphate‐buffered	saline	
PMA	 	 	 Phorbol	myristate	acetate	
PPD	 	 	 Purified	protein	derivative	(of	M.	tuberculosis)	
RAG	 	 	 Recombination	activating	gene	
SD	 	 	 Standard	deviation	
SEM	 	 	 Standard	error	of	the	mean	
TB	 	 	 Tuberculosis	
TGF‐		 	 Transforming	growth	factor	beta	
Th1	 	 	 T	helper	type	1	
Th2	 	 	 T	helper	type	2	
TNF‐		 	 Tumour	necrosis	factor	alpha	
Treg	 	 	 Regulatory	T	cell	
Tr1	 	 	 Type	1	regulatory	T	cell	






Tuberculosis	 (TB)	 has	 been	 declared	 a	 global	 emergency	 by	 the	World	Health	
Organisation	(WHO)	(WHO,	2003).	 It	 is	estimated	 that	one‐third	of	 the	world’s	
population	is	 infected	annually,	and	in	2009	there	was	an	estimated	9.4	million	
cases	 of	 TB	 globally,	 with	 an	 approximate	 1.3	 million	 people	 dying	 from	 TB	
(WHO,	2010).	Although	there	is	a	high	cure	rate	with	appropriate	anti‐TB	drugs,	
the	 failure	 to	 stem	 the	 tide	 with	 drugs	 is	 related	 to	 numerous	 social,	 public	





2003).	 A	 highly	 genetically‐related	 species,	 M.	 bovis	 bacille	 Calmette‐Guérin	
(BCG),	has	been	used	as	a	live	attenuated	vaccine	for	almost	a	century,	and	there	
is	 no	 clinically	 available	 alternative	 at	 present.	 However,	 the	 exact	 immune	
mechanisms	 through	which	 BCG	 protection	 is	 conferred	 remain	 unclear.	More	
importantly,	the	protective	efficacy	of	BCG	against	adult	pulmonary	TB,	which	is	
the	most	prevalent	form	of	TB,	ranges	from	0‐80%	across	different	parts	of	the	
world	 (Fine	and	Vynnycky,	1998).	 	 Strain	differences,	 geographical	 factors	 and	
reinfection	pathways	(Smith,	2000;	Fine,	2001a)	have	been	suggested	as	causes,	
but	 the	most	widely	 supported	 hypothesis	 for	 the	 failure	 of	 BCG	 is	 that	 prior	
exposure	to	environmental	mycobacteria	(Env)	affects	how	the	host	responds	to	
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Prior	 exposure	 to	 certain	 Env	 species	 blocks	 the	 replication	 of	 BCG	 (Brandt,	
2002;	 Demangel,	 2005)	 or	 modifies	 the	 nature	 of	 immunity	 induced	 by	 BCG	
(Young,	2007).	The	persistence	of	the	Env	species	in	the	host	and	the	relatedness	
between	 the	 priming	 Env	 strain	 and	 BCG	 have	 been	 suggested	 as	 factors	
influencing	 these	 effects.	 Env	 exposure	 following	 BCG	 vaccination	 can	 also	
modulate	 protective	 immunity	 generated	 by	 BCG	 in	 mice	 (Flaherty,	 2006).	
Infants	 with	 delayed	 BCG	 vaccination,	 allowing	 time	 for	 Env	 exposure,	 have	
poorer	 IFN‐γ	 responses	 to	BCG	antigens	after	vaccination	 (Burl,	2010)	and	yet	
early	neonatal	 vaccination	of	 those	 living	 in	 areas	with	high	prevalence	of	Env	






isolated	 in	 Singapore,	 there	was	 strongest	 cytolytic	 activity	 against	 autologous	
BCG‐infected	 monocytes	 with	 Mycobacterium	 chelonae	 (CHE)	 stimulation,	
implying	best	 cross‐reactive	cytotoxicity	 (Zhang	Lin,	MSc	 thesis).	This	 suggests	
that	 CHE	 priming	 had	 strongest	 potential	 to	 influence	 BCG	 responses.	 	 This	
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outcome	 was	 subsequently	 replicated	 in	 mice	 after	 in	 vivo	 intra‐peritoneal	
sensitisation	with	various	Env	species,	and	again	CHE	exposure	led	to	strongest	
cytotoxic	 responses	 against	 BCG‐infected	 autologous	macrophages	 (Ho,	 2009).	
This	led	to	our	choice	of	using	CHE	sensitisation	as	a	model	for	Env	exposure	in	






BCG	 fails	 will	 allow	 development	 of	 vaccines	 that	 do	 not	 have	 similar	 pitfalls.	
This	 is	 especially	 pertinent	 given	 that	 several	 vaccines	 in	 the	 pipeline	 are	
actually	modified	strains	of	BCG	(Kaufmann,	2010b).		
	
This	 work	 investigated	 the	 hypotheses	 that	 Env	 sensitisation	 induced	 both	




1) In	 CHE‐sensitised	 mice,	 to	 analyse	 the	 role	 of	 different	 cell	 types,	
cytokine	factors	and	mediators	of	cytotoxicity	on	the	host’s	responses	to	
BCG,	and	their	subsequent	impact	on	BCG	survival.		
2) To	 investigate	 the	 role	 of	 CD4+CD25+	 regulatory	 T	 cells	 (Tregs)	 from	




3) To	 investigate	 how	 variations	 on	 multiple	 sensitisation	 parameters	
(dose,	timing,	in	vivo	persistence	of	CHE	and	viability	of	CHE)	affect	Treg	
phenotypes	 and	 systemic	Th1	 responses	 induced	by	CHE	 sensitisation,	
before	and	after	subsequent	BCG	vaccination.			
4) In	 a	 model	 of	 BCG	 vaccination	 of	 weanling	 mice	 that	 mimics	 human	
neonatal	 BCG	 vaccination,	 to	 characterise	 the	 influence	 of	 post‐






Tuberculosis	 (TB)	 in	 humans	 is	 caused	 by	 Gram‐negative	 bacteria	 collectively	




the	 world’s	 population	 is	 latently	 infected,	 with	 the	 potential	 for	 reactivation	
(WHO,	 2010).	 Majority	 of	 the	 cases	 of	 TB	 occur	 in	 Asia	 and	 Africa,	 with	 the	
highest	TB	incidence	in	India,	China,	South	Africa,	Nigeria	and	Indonesia	(WHO,	
2010).	 In	 Singapore,	 TB	 is	 of	moderate	 endemicity,	with	 near	 1500	 new	 cases	
each	year,	more	than	half	being	elderly	males.	A	vast	majority	of	these	cases	are	







cough,	 fever	 and	 weight	 loss.	 Extrapulmonary	 TB	 can	 involve	 any	 organ,	 but	
lymphadenitis	 and	 pleuritis	 with	 effusion	 are	 most	 common,	 while	 miliary	
disease	 and	 meningitis	 are	 the	 most	 fatal	 forms.	 The	 spread	 of	 TB	 infection	
occurs	 through	 the	 inhalation	 of	 airborne	 droplets	 of	 respiratory	 secretions	
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carrying	 Mtb	 bacteria,	 which	 are	 generated	 when	 infected	 individuals	 cough,	
sneeze,	 talk,	 or	 spit	 (Dye,	 2006).	 Less	 than	 five	 percent	 of	 infected	 individuals	
develop	progressive	disease	within	 five	years	of	Mtb	 infection,	 after	which	 the	
risk	of	reactivation	of	latent	TB	is	even	lower	(Dye	and	Floyd,	2006).		
	
TB	can	be	 treated	with	a	 cocktail	of	 antibiotics,	primarily	 isoniazid,	 rifampicin,	
pyrazinamide	 and	 ethambutol.	WHO	 recommends	 directly	 observed	 treatment	
short	 course	 (DOTS),	 a	 strategy	 for	 administering	 treatment	 under	 direct	
observation.	 Issues	 contributing	 to	 continued	 TB	 transmission	 include	
inaccessibility	 of	 drugs,	 poor	 compliance	 to	 the	 prolonged	 course	 of	
chemotherapy	(six	months	minimum),	overcrowded	living	conditions	associated	
with	poverty	in	certain	communities,	the	rise	of	human	immunodeficiency	virus	





Mtb	 is	 an	 intracellular	 pathogen	 that	 survives	 within	 lung	 macrophages.		
Alveolar	macrophages,	believed	to	be	the	primary	host	cells	of	Mtb,	function	both	
as	 a	 first	 line	 of	 cellular	 defence,	 as	well	 as	 a	 niche	 for	 bacterial	 survival	 and	
replication.	Mtb	can	interfere	with	membrane	trafficking,	neutralise	phagosomal	
pH	and	avoid	phagolysosomal	fusion,	allowing	them	to	escape	the	host	immune	





can	 also	 migrate	 to	 the	 draining	 lymph	 nodes,	 where	 they	 then	 present	 Mtb	
antigens	 to	 T	 cells	 and	 initiate	 T	 helper	 type	 1	 (Th1)	 responses.	 Granulomas	




some	 evidence	 that	 latent	 mycobacteria	 survive	 within	 granulomas,	 where	
conditions	 are	 hypoxic	 and	 generally	 nutrient‐deprived,	 by	 reducing	 their	




The	 intracellular	 lifestyle	 of	 Mtb	 places	 cell‐mediated	 immunity	 in	 greater	
prominence	than	antibodies	in	anti‐TB	immunity.	The	major	cell	types	involved	





seen	 in	 the	 marked	 susceptibility	 of	 HIV‐positive	 patients,	 who	 have	 reduced	
CD4+	T	 cell	 counts	 (Flynn	 and	Chan,	 2001;	 Elkins,	 2003).	 Effector	mechanisms	
that	CD4+	T	cells	engage	to	fight	Mtb	are	still	being	elucidated.	CD4+	Th1	memory	
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cells	 are	 crucial	 in	 mediating	 long‐term	 protection	 against	 TB	 (Sutherland,	
2010).	They	produce	a	variety	of	pro‐inflammatory	cytokines	such	as	IL‐2,	TNF‐α	
and	 IFN‐	 that	 are	 critical	 in	 the	 process	 (Flynn,	 1993;	 Flynn,	 1995;	 Cooper,	
2009).	 IFN‐	 production	 in	 response	 to	 infected	 macrophages	 presenting	
Mycobacterium	 antigens	 is	 a	 key	 effector	mechanism	of	 CD4+	 cells,	which	 then	
activate	macrophages	to	kill	the	bacteria	harboured	within	by	producing	reactive	
nitrogen	 and	 oxygen	 species	 and	 promoting	 phagolysosome	 fusion	 (Flynn	 and	
Chan,	 2001;	 MacMicking,	 2003).	 The	 magnitude	 of	 polyfunctional	
Mycobacterium‐specific	Th1	cells,	secreting	multiple	cytokines,	in	the	lungs	after	
murine	Mtb	 challenge	 is	 apparently	 correlated	with	 protection	 against	 disease	
(Forbes,	 2008).	 However,	 TB	 patients	 have	 higher	 frequencies	 of	 such	





CD4+	T	 cells	 are	 largely	 known	 to	 function	 as	 helper	T	 cells,	 but	 they	 can	 also	
exhibit	 cytotoxic	 activity.	 After	 in	 vitro	 stimulation	 with	 Mtb,	 upregulation	 of	
mRNA	 for	 perforin,	 granulysin,	 and	 granzymes	A	 and	B	 is	 observed	 in	 CD4+	 T	
cells	from	healthy	tuberculin	skin‐test	positive	individuals	(Canaday,	2001).	This	
indicates	 a	 cytolytic	 role	 of	 these	 cells	 against	TB.	 In	 addition,	 CD4+	 cells	 from	
peripheral	 blood	 of	 patients	with	 active	TB	display	 cytolytic	 responses	 against	
autologous	Mtb‐pulsed	macrophages,	and	such	activity	diminishes	with	severity	
of	TB	 (De	La	Barrera,	2003).	However,	 it	 is	unclear	whether	 the	opposite,	 that	
patients	 with	 less	 severe	 TB	 have	 better	 cytotoxic	 responses,	 holds	 true.	 The	
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same	study	shows	that	the	CD4‐mediated	cytotoxicity	observed	is	dependent	on	






important	 in	 immunity	 against	 TB	 (Lewinsohn,	 1998;	 Sousa,	 2000;	 van	
Pinxteren,	 2000).	 The	 essentiality	 of	 CD8+	 T	 cells	 in	murine	 TB	 immunity	 has	
been	proven	in	some	studies	(Flynn,	1992;	Rolph,	2001),	but	disputed	by	others	
(Mogues,	2001).	Reduced	numbers	of	antigen‐specific	effector	memory	CD8	cells	
have	 been	 linked	 to	 the	 poorer	 antimicrobial	 activity	 of	 patients	 on	 anti‐TNF	
therapy,	 with	 associated	 increased	 TB	 incidence	 (Bruns,	 2009).	 Although	 the	
major	 effector	 function	 of	 CD8+	 T	 cells	 is	 cytotoxicity	 against	 infected	 cells,	




contents.	 In	 humans,	 CD8+	 T	 cells	 exert	 cytotoxicity	 on	 Mtb‐infected	
macrophages	 via	 a	 granule	 (perforin/	 granzyme	 or	 granulysin)‐dependent	
mechanism	 that	 is	 independent	 of	 Fas/	 Fas‐ligand	 interaction	 (Stenger,	 1997;	
Stenger,	1998).	In	mice,	one	study	claims	that	the	perforin/	granzyme	pathway	is	




granule	 exocytosis	 is	 required	 for	 the	 cytolytic	 activity	 of	 human	 CD8+	 T	 cells	
(Canaday,	 2001).	 CD8+	 responses	 are	 elicited	 via	 the	major	 histocompatibility	
complex	 (MHC)	 Class	 I	 pathway,	 which	 requires	 antigen	 presentation	 in	 the	
cytosol.	As	Mtb	resides	in	the	phagosome,	its	antigens	are	not	usually	available	in	
the	 cytosol.	However,	Mtb	 can	egress	 into	 the	 cytosol	 of	 infected	DCs	 (van	der	
Wel,	2007),	otherwise,	apoptosis	of	infected	macrophages	can	also	lead	to	cross‐




Mtb	 readily	 activates	 	 T	 cells	 and	 induces	 	 T	 cell–mediated	 production	 of	
antigen‐specific	IFN‐	(Ladel,	1995).		T	cells	are	also	a	primary	source	of	IL‐17	
(Lockhart,	2006).	Mice	with	T	cell	 receptor	 (TCR)		 gene	deletions	succumb	 to	
Mtb	infection,	while	immunocompetent	control	mice	survive,	demonstrating	the	
protective	role	of		T	cells	 in	TB	(Ladel,	1995).	 In	addition,		T	cell‐mediated	
lytic	activity	 is	observed	 in	ex	vivo	 effector	cells	 from	TB	patients,	suggesting	a	
cytolytic	role	for	these	cells	in	TB	(De	La	Barrera,	2003).	The	expansion	of		T	
cells	with	BCG,	from	peripheral	blood	lymphocytes	of	tuberculin‐positive	donors,	






Natural	 killer	 (NK)	 cells	 are	 cytolytic	 effector	 cells	 of	 innate	 immunity.	Human	
studies	 have	 demonstrated	 that	 NK	 cells	 respond	 to	 live	 Mtb	 in	 vitro	 and	
increased	 NK	 activity	 is	 observed	 in	 active	 pulmonary	 TB	 patients	 (Yoneda,	
1983;	Esin,	1996).	In	murine	studies	with	Mycobacterium	bovis	bacille	Calmette‐	
Guérin	(BCG)	or	Mtb	infection,	expansion	of	NK	cells	is	observed	(Falcone,	1993;	





CD1‐restricted	 T	 cells	 recognise	 lipid	 antigens	 and	 can	 be	 double	 negative	 for	
CD4	and	CD8	 (Porcelli,	 1992),	 or	 expressing	CD4	or	CD8	 (Rosat,	 1999;	 Sieling,	
2000).	 CD1‐restricted	T	 cells	 are	 involved	 in	 immune	 responses	 against	Mtb	 –	
they	recognise	lipid	and	glycolipid	antigens	of	Mtb	and	kill	infected	macrophages	
(Stenger,	1997).	Mycobacteria‐specific	CD1‐restricted	T	cell	 clones	mostly	have	
Th1	 functions,	 producing	 high	 levels	 of	 IFN‐	 and	TNF‐	 (Rosat,	 1999;	 Sieling,	
2000).	 CD1‐restricted	 T	 cells	 that	 are	 highly	 proliferative	 and	 IFN‐	 secreting,	
predominantly	 of	 the	 CD4	 subset,	 are	 also	 found	 in	 patients	 with	 active	 TB	
(Ulrichs,	2003).	CD1‐restricted	T	cells	also	contain	perforin	and	granulysin	and	






antibodies	 against	 certain	 mycobacteria‐derived	 products	 can	 protect	 TB	 in	
murine	 models	 (Teitelbaum,	 1998;	 Pethe,	 2001;	 Hamasur,	 2004),	 either	 by	
reducing	 bacterial	 burden	 or	 limiting	 inflammatory	 progression	 (Glatman‐
Freedman,	 2006).	 	 B	 cells	 also	 function	 as	 antigen‐presenting	 cells	 and	 can	
influence	 host	 immunity	 by	 engaging	 Fc	 receptors	 by	 antibodies	 during	 Mtb	
infections,	leading	to	an	impact	on	Th1	activation	(Maglione	and	Chan,	2009).	B	
cells	are	also	responsible	for	granuloma	formation	by	surrounding	Mtb	bacteria.	






and	 these	 cells	 can	 influence	 the	 type	 of	 T	 cell	 responses	 mounted	 during	
infection	 (Dorhoi	 and	 Kaufmann,	 2009).	 The	 cytokines	 secreted	 by	 antigen	
presenting	 cells	 can	polarise	TB	 responses,	 such	as	 the	production	of	 IL‐23	by	
DCs	 that	 stimulates	 polarisation	 of	 Th17	 responses	 (Dorhoi	 and	 Kaufmann,	
2009).	The	engagement	of	different	receptors	on	antigen	presenting	cells	results	
in	 different	 responses	 primed,	 an	 example	 being	 the	 promotion	 of	 Treg	






contain	Mtb,	yet	 this	knowledge	 is	crucial	 for	designing	an	optimal	TB	vaccine.	
Whether	 effector	 cells	 or	memory	 cells	 are	more	 important	 for	protection	 still	
remains	 a	 question,	 as	 the	 former	 protects	 during	 early	Mtb	 infection	 and	 the	
latter	in	long‐term	immunity	(Kaufmann,	2010a).	Additionally,	amongst	effector	
T	 cells,	 it	 is	 still	 unclear	 whether	 only	 some	 or	 all	 of	 effector	 T	 cells,	 which	
include	CD4+	Th1	cells,	CD8+	cells,	the	cytolytic	cells	and	Th17	cells,	are	required	
during	 early	 infection	 (Kaufmann,	 2010a).	 For	 long‐term	 immunity,	 questions	
remain	 about	 whether	 effector	 memory	 cells	 that	 reside	 at	 the	 active	 Mtb	




The	 only	 currently	 available	 human	 vaccine	 against	 TB	 is	 live	M.	 bovis	 bacille	
Calmette‐Guérin	 (BCG),	 originating	 in	 Institut	 Pasteur	 from	 repeated	 in	 vitro	
passage	 of	 a	 virulent	 M.	 bovis	 strain	 to	 achieve	 attenuation.	 The	 WHO	
recommends	 BCG	 vaccination	 at	 birth,	 especially	 in	 TB	 endemic	 areas,	 but	
alternative	vaccination	policies	exist	(Fine,	1999).	 	 In	the	United	Kingdom	(UK)	
and	 some	 nations	 in	 Europe,	 BCG	 is	 administered	 once	 during	 childhood	 or	
adolescence	(12‐13	year	olds),	although	some	health	authorities	in	these	regions	
have	 currently	 moved	 to	 vaccinating	 only	 high‐risk	 populations	 (Fine,	 1999).	
Repeated	or	boosting	BCG	vaccination	regimen	is	used	in	some	countries,	such	as	
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BCG	 vaccines	 are	 now	 distributed	 in	 lyophilised	 form,	 ranging	 from	
approximately	0.35	x	106	to	106	culturable	particles	per	dose	(Fine,	1999).	The	






response	 by	 measuring	 the	 delayed	 type	 hypersensitivity	 response	 to	 intra‐
dermal	PPD	(Fine,	1999).	Purified	protein	derivative	of	Mtb	(PPD)	contains	Mtb	
protein	antigens,	many	of	which	are	conserved	within	the	Mycobacterium	genus.	
The	 Mantoux	 method	 of	 skin‐testing	 requires	 reading	 the	 diameter	 of	 skin	
induration	 48	 h	 after	 PPD	 administration,	 and	 BCG‐induced	 reactivity	 to	
tuberculin	could	yield	a	0	–	19	mm	induration	(Karalliedde,	1987).	Some	factors	
that	 contribute	 to	 the	 varying	 size	 of	 the	 tuberculin	 skin	 reaction	 post‐BCG	
vaccination	 include	 the	 dose	 (Ashley	 and	 Siebenmann,	 1967),	 method	 of	
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vaccination	 (Landi,	 1967),	 geographical	 location,	 which	 is	 also	 linked	 to	
environmental	 mycobacteria	 (Env)	 exposure	 (Floyd,	 2002),	 and	 the	
manufacturer	 of	 the	 vaccine	 (Horwitz	 and	 Bunch‐Christensen,	 1972).	 Prior	
asymptomatic	Mtb	exposure	or	latent	TB	would	also	increase	the	PPD	response,	
as	evidenced	from	the	use	of	the	Mantoux	test	to	detect	latent	TB	(Schluger	and	
Burzynski,	 2010).	 These	 factors	 complicate	 the	 interpretation	 of	Mantoux	 test	
results.		
	




Such	 IFN‐	 responses	 are	 expected	 to	 increase	 in	 vaccinated	 individuals	
following	BCG	vaccination	(Black,	2002),	but	these	responses	start	waning	by	9	


























Gorak‐Stolinska,	 2006),	 BCG	 dose	 (Davids,	 2007),	 host	 genetic	 variations,	
vaccination	route	(Davids,	2006)	and	interference	with	BCG‐mediated	responses	
through	 exposure	 to	 Env	 (Fine,	 1999;	 Black,	 2001a;	 Weir,	 2006)	 Protection	
attributable	 to	 BCG	 is	 particularly	 low	 in	 developing	 countries	 with	 high	 TB	
incidence,	such	as	parts	of	Asia	and	Africa.	This	coincides	with	tropical	regions	






does	 not	 generate	 protective	 immunity	 (Orme,	 1988;	 Daugelat,	 1995).	 BCG	
manufacturers	have	 traditionally	performed	batch‐testing	 for	efficacy	based	on	
tuberculin	 conversion	 in	 guinea	 pigs.	 	 In	 research,	 BCG	 efficacy	 is	 usually	
determined	 by	 challenging	 BCG‐vaccinated	 mice	 with	 low	 dose	 Mtb	 via	 the	
aerosol	 route	 30	 days	 after	 vaccination,	 then	 enumerating	 the	 lung	 bacterial	
burden	one	month	post‐infection	(Orme,	2005).	BCG	reduces	Mtb	counts	in	the	
lungs	of	vaccinated	mice	or	guinea	pigs	by	1	–	1.3	log	or	2	–	3	log	respectively,	
about	 a	 month	 after	 aerosol	 challenge	 with	 low‐dose	 virulent	 Mtb	 (Huygen,	
1996;	Skeiky,	2004;	Castanon‐Arreola,	2005;	Orme,	2005).	Guinea	pigs	develop	
granulomas	histologically	similar	to	those	in	active	TB	patients,	and	can	be	used	
for	both	 short‐term	protection	 studies	and	chronic	disease	models	 (McMurray,	
1996;	Baldwin,	1998;	McMurray,	2001).	Mice	are	naturally	more	resistant	to	TB	
and	 prime	 stronger	 immune	 responses.	 BCG	 usually	 takes	 a	 chronic	 course	 in	
mice,	 with	 development	 of	 long‐lasting	 immunity	 (Blanden,	 1969).	 A	
subcutaneous	dose	of	BCG	is	still	protective	30	weeks	after	vaccination	(Aldwell,	
2006).	However,	BCG‐vaccinated	mice	do	not	achieve	sterile	eradication	of	Mtb,	






BCG	 vaccination	 was	 initially	 administered	 to	 humans	 orally.	 Oral	 vaccination	
requires	 a	 larger	 dose	 (higher	 costs),	 and	 oropharyngeal	 infection	 or	
intussusception	 in	 children	 due	 to	 enlarged	 Peyer’s	 patches	 are	 potential	
complications.	 Therefore,	 BCG	 is	 now	 most	 commonly	 administered	 via	 the	
intra‐dermal	 route,	 which	 is	 also	 more	 efficient	 at	 inducing	 tuberculin	
conversion	(Fine,	1999).		
	
Different	 routes	 of	 BCG	 administration	 prime	 different	 immune	 responses.		
Higher	 levels	 of	 Th1	 cytokines	 in	 both	 CD4+	 and	 CD8+	 cells	 are	 observed	with	




Protection	 afforded	 by	 BCG	 against	 murine	 TB	 infection	 also	 appears	
independent	 of	 the	 administration	 route,	 be	 it	 the	 subcutaneous,	 intravenous,	
rectal	or	aerosol	route	(Abolhassani,	2000;	Lagranderie,	2000;	Palendira,	2002),	
although	 immune	 changes	 induced	 may	 differ	 widely.	 The	 intravenous	 route	
yields	higher	 frequencies	of	 IFN‐	producing	CD4+	and	CD8+	cells	 than	 the	oral	
route	(Mittrucker,	2007).	Recruitment	of	activated	memory	CD44hiCD62Llo	CD4+	
memory	T	cells	to	the	lungs	is	fastest	and	highest	in	mice	given	inhaled	BCG	via	
aerosol,	 followed	 by	 the	 intravenous	 then	 the	 subcutaneous	 route	 (Palendira,	
2002).	In	these	studies,	however,	the	differential	routes	and	immune	responses	




closely	 mimics	 what	 happens	 in	 humans,	 even	 though	 the	 inhaled	 route	 of	
administration	is	likely	to	better	engage	local	responses	in	the	lungs	and	protects	
mice	 against	 inhaled	 TB	 infection	 (Falero‐Diaz,	 2000).	 The	 disadvantage	 of	





Vaccination‐induced	 protection	 against	 TB	 has	 been	 thought	 to	 depend	 on	 the	
generation	of	antigen‐specific	CD8+	(Wang,	2004;	Begum,	2009)	cytotoxic	T	cells	
as	 well	 as	 CD4+	 Th1	 T	 cell	 subsets	 together	 with	 the	 induction	 of	 IFN‐	
(Pedrazzini,	1987;	Yang	and	Mitsuyama,	1997).	However,	 the	understanding	of	






mainly	 of	 the	 effector	 phenotype	 (Soares,	 2008).	 The	 magnitude	 of	 IFN‐	
production	following	BCG	vaccination	has	been,	for	a	long	time,	considered	a	key	
immune	correlate	of	protection	(Huygen,	1992).	Previously	BCG‐vaccinated	HIV	
patients	 with	 higher	 baseline	 IFN‐	 responses	 to	 Mtb	 antigens	 have	 a	
significantly	lower	risk	for	TB	infection	when	followed	up	prospectively	(Lahey,	
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2010).	However,	 there	 is	no	correlation	between	BCG‐induced	 IFN‐	 responses	
and	 protection	 in	 mice	 (Mittrucker,	 2007).	 Moreover,	 some	 candidate	 TB	
vaccines	that	induce	higher	levels	of	IFN‐	production	than	BCG,	are	nonetheless	
less	 protective	 than	 BCG	 in	 terms	 of	 reducing	 TB	 bacterial	 burden	 in	 animals	





In	 BCG‐vaccinated	 humans	 and	 mice,	 majority	 of	 the	 cells	 produce	 single	
cytokines,	i.e.	different	cells	secreting	just	IFN‐,	TNF‐	or	IL‐2	(Li,	2010),	while	
other	 cells	 are	 polyfunctional	 and	 can	 produce	 these	 multiple	 cytokines	
simultaneously	 (Beveridge,	 2007;	 Soares,	 2008).	 Mycobacterium‐specific	
polyfunctional	T	cells	at	the	infection	site	have	been	associated	with	protection	
against	 TB	 challenge	 (Forbes,	 2008).	 However,	 the	 latest	 large‐scale	 neonatal	
BCG	 vaccination	 study	 involving	multi‐cytokine	 comparisons	 of	 those	who	 did	
and	 did	 not	 succumb	 to	 TB	 within	 two	 years	 suggests	 that	 frequency	 and	





in	 humans	 (Kaufmann	 and	 McMichael,	 2005).	 However,	 BCG‐vaccinated	
macaques,	 if	 depleted	 of	 CD8+	 cells,	 have	 diminished	 immunity	 to	 subsequent	
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Mtb	 challenge	 (Chen,	 2009).	 Moreover,	 BCG‐specific	 proliferating	 CD8+	 T	 cells	
with	functional	cytotoxic	potential	are	present	in	peripheral	blood	of	vaccinated	
infants,	 ten	weeks	 post‐vaccination	 (Hanekom,	 2005).	 The	 presence	 of	 CD8+	 T	
cells,	 in	 the	 absence	 of	 CD4+	 T	 cells	 in	 CD4	 knock‐out	 mice,	 is	 sufficient	 to	
mediate	protection,	albeit	delayed,	post‐BCG	vaccination	in	mice,	and	this	effect	
is	 independent	of	the	viability	of	BCG	(Wang,	2004).	The	rapid	accumulation	of	
CD8+	 T	 cells	 after	 TB	 challenge	 in	 the	 infected	 tissues	 of	 BCG‐vaccinated	mice	
correlates	better	with	protection	than	IFN‐	secretion	(Mittrucker,	2007).		CD8+	
T	cells	induced	by	BCG	have	cytolytic	function	(Turner	and	Dockrell,	1996),	are	




Suppressor	 responses	 have	 long	 been	 known	 to	 occur	 with	 BCG	 vaccination	
(Bennett,	1978)	but	induction	of	naturally	occurring	and	inducible	regulatory	T	
cells	 (Tregs)	 in	 Mycobacterium	 infections	 has	 been	 fairly	 recently	 described.	
Expansion	of	Tregs,	both	at	disease	sites	and	in	peripheral	blood,	are	observed	in	
human	 TB	 studies,	 and	 has	 been	 linked	 to	 depressed	 immunity	 (Guyot‐Revol,	
2006;	 Hougardy,	 2007a;	 Li,	 2007).	 An	 increase	 in	 CD4+CD25+	 Treg	 and	 FoxP3	
expression,	together	with	an	increase	in	the	level	of	anti‐inflammatory	cytokines	
IL‐10	 and	 TGF‐,	 is	 associated	 with	 BCG	 treatment,	 demonstrating	 that	 BCG	
induces	 Tregs	 (Li	 and	 Shen,	 2009).	 Even	 in	 human	 neonates,	 BCG	 vaccination	
induces	 CD4+CD25+FoxP3+	 natural	 Tregs	 (Burl,	 2010).	 Some	 suggest	 that	
CD4+CD25+	 cells	 contribute	 to	 the	 IL‐10	 production	 after	 BCG	 vaccination	
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(Akkoc,	 2010)	 but	 others	 have	 described	 lung	 cells	 (Mendez‐Samperio,	 2008)	
and	 inducible	 Tregs	 (Soares,	 2008)	 as	 being	 responsible	 for	 increased	 IL‐10	
production	 in	 response	 to	 BCG	 vaccination.	 A	 murine	 study	 by	 Quinn	
demonstrates	 that	 antibody	 inactivation	 of	 natural	Tregs	 –	CD25+	 cells	 –	 three	
days	before	BCG	vaccination	increases	the	proportion	and	frequency	of	antigen‐
specific	 IFN‐	 producing	 CD4+	 and	 CD8+	 T	 lymphocytes	 post‐vaccination.	
Secondary	responses	 to	a	 subsequent	BCG	challenge	occur	earlier	 than	 in	non‐
Treg	depleted	mice,	without	 adverse	 impact	 on	 immune	protection	 against	 TB	
(Quinn,	2006).	This	suggests	that	natural	Tregs	do	not	have	a	direct	role	to	play	
in	BCG	induced	protection.	A	separate	study	by	Jaron,	however,	contradicts	this.	
Jaron	 finds	 that	 murine	 BCG	 vaccination	 causes	 Treg	 recruitment	 to	 draining	
lymph	 nodes,	 and	 they	 suppress	 anti‐mycobacteria	 CD4+,	 but	 not	 CD8+,	 T	 cell	
responses	(Jaron,	2008).	Moreover,	CD25+	Treg	depletion	led	to	a	significant	but	
moderate	 reduction	 in	 lung	Mtb	 load	after	BCG	vaccination	and	Mtb	challenge,	





The	 failure	 of	 BCG	 to	 protect	 against	 adult	 pulmonary	 TB	 and	 latent	 TB	 has	
prompted	efforts	to	develop	more	efficacious	vaccine	strategies.	Many	candidate	





may	 be	 unethical	 not	 to	 include	 BCG	 in	 any	 vaccine	 strategies	 (Andersen	 and	
Doherty,	2005).	Hence,	 to	retain	the	protective	effects	observed	 in	childhood,	a	





Although	 protection	 attributable	 to	 BCG	 is	 shown	 to	 be	 life‐long	 in	 Alaskan	





BCG30,	 which	 simply	 over‐expresses	 the	 immunodominant	 secretory	 antigen	
Ag85B	(Horwitz,	2000).	Improvement	of	antigen	presentation	has	been	achieved	
by	 rBCGure‐Hly,	 a	 modified	 BCG	 strain	 expressing	 listeriolysin	 that	 causes	
perforation	in	phagosomes,	allowing	BCG	to	egress	into	the	cytosol,	and	induces	
apoptosis	 of	 infected	 macrophages,	 thereby	 inducing	 cross‐priming	 and	







Hence,	 there	 are	 scientists	 investigating	 subunit	 vaccine	 boosting	 after	 BCG	
priming	(Schneider,	1998;	McShane,	2001;	McConkey,	2003).	Viral	vectors	have	
been	 used	 in	 such	 vaccines,	 and	 one	 example	 is	 the	 modified	 vaccinia	 virus	
Ankara	(MVA85A),	expressing	Ag85A	(McShane,	2004;	Sander,	2009).	Given	that	
Ag85A	 is	shared	between	BCG	and	Mtb,	 it	 is	an	appropriate	antigen	to	evoke	a	
true	 booster	 response	 (Kaufmann,	 2010a).	 Improvements	 of	 subunit	 vaccine	








vaccines	 therefore	 try	 to	 achieve	 further	 attenuation	 of	 BCG,	 such	 as	 through	








The	 aforementioned	 vaccines	 in	 research	 are	 designed	 as	 pre‐exposure	
prophylactic	 vaccines,	 and	 therefore	 neither	 protect	 against	 development	 of	
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latent	TB	nor	prevent	reactivation	of	latent	TB.	Hence,	scientists	believe	that	the	
next	 generation	 of	 novel	 TB	 vaccines	 should	 target	 dormant	 Mtb	 and	 control	
reactivation	 for	 the	 lifetime	 of	 an	 infected	 individual	 (Kaufmann,	 2006;	
Kaufmann).	 This	 requires	 a	 pre‐exposure	 vaccination	 strategy	 that	will	 induce	
immune	 mechanisms	 that	 are	 able	 to	 contain	 Mtb	 and	 sustain	 lifelong	
containment,	as	well	as	a	post‐exposure	vaccine	that	will	restimulate	memory	T	
cells	 and	 promote	 strong	 effector	 T	 cell	 responses	 specific	 for	 Mtb	 upon	
reactivation	 (Kaufmann,	 2010a).	 There	 is	 interest	 in	 developing	 vaccines	







genus	 causing	 severe	 human	 disease,	 and	 these	 are	 obligate	 intracellular	
bacteria.	 However,	 there	 are	 numerous	 species	 of	 mycobacteria	 that	 are	 free‐
living	and	ubiquitously	found	in	soil,	open	waters	and	even	urban	water	supplies	
(Chakrabarti,	 1990;	 Falkinham,	 2001),	 hence	 they	 are	 called	 environmental	
mycobacteria	 (Env)	 or	 non‐tuberculous	 mycobacteria.	 Many	 of	 these	 are	
potentially	 pathogenic	 but	 opportunistic.	 Env	 were	 thought	 to	 rarely	 cause	
human	 disease,	 except	 upon	 direct	 inoculation	 or	 in	 immunocompromised	
individuals	(Primm,	2004),	where	infection	most	frequently	occurs	in	the	lungs,	
skin	 and	 cervical	 lymph	 nodes	 (Wayne	 and	 Sramek,	 1992;	 Tortoli,	 2003).	
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However,	there	is	increasing	recognition	that	immunocompetent	adults	can	also	
suffer	 from	 self‐limited	 cutaneous	 to	 widespread	 Env	 infections	 such	 as	
lymphadenitis	 and	 disseminated	 disease	 (Jarzembowski	 and	 Young,	 2008).	
Asymptomatic	 colonisation	 can	 occur	 in	 immunocompetent	 individuals.	 Many	
Env	species	are	genetically	closely	related	to	BCG	(average	>95%	similarity)	and	





groups	 (Runyon	 Classification)	 according	 to	 their	 growth	 rate	 and	 pigment	
production	 (Timpe	 and	 Runyon,	 1954).	 Slow‐growers	 (Groups	 I,	 II,	 III)	 are	
distinguished	from	fast‐growers	(Group	IV)	based	on	whether	the	bacteria	grow	
on	 agar	 after	 seven	 days.	 These	 are	 further	 divided	 into	 groups	 depending	 on	
their	 ability	 to	 produce	 pigment.	 Slow	 growers	 include	 pathogens	 such	 as	M.	
kansasii,	M.	marinum,	M.	 scrofulaceum,	M.	 szulgai,	M.	avium‐intracellulare	 (also	
known	 as	 M.	 avium	 complex)	 and	 the	 non‐pathogenic	 M.	 gordonae	 and	 M.	
flavescens.	 Fast‐growing	 Env	 include	 pathogens	 such	 as	 M.	 fortuitum	 and	 M.	
chelonae	(CHE)	and	non‐pathogenic	M.	smegmatis	and	M.	vaccae.	 Slow	growing	



















T	 cell,	 IFN‐	 or	 TNF‐	 knock‐out	 mice	 have	 higher	 organ	 loads	 of	 Env	 when	
infected,	compared	to	wild‐type	mice,	indicating	the	importance	of	these	factors	in	
defending	against	Env	infections	(Byrd	and	Lyons,	1999;	Rottman,	2007).	Env	also	




exposure	 stimulates	 cell‐mediated	 immune	 responses,	which	 can	 be	measured	
both	 in	 vitro	 (Black,	 2001a)	 and	 as	 a	 skin	 test	 (Fine,	 2001b;	 Weir,	 2003).	 In	





the	 strength	 of	 responses	 elicited	 (Black,	 2001a).	 These	 findings	 suggest	 that	
different	species	of	Env	elicit	different	immune	responses,	usually	as	a	result	of	
their	 phylogenetic	 distance	 from	 one	 another.	 In	 murine	 studies,	 the	 slow‐
growing	Env	species	M.	avium	and	M.	scrofulaceum	elicit	stronger	responses	than	
the	 fast‐growing	 M.	 vaccae	 (Demangel,	 2005),	 possibly	 related	 to	 their	
persistence	 in	 hosts.	When	 six	 different	 isolates	 of	 Env	 from	 soil	 and	 sputum	
samples	from	Malawi	were	administered	intravenously	in	mice,	the	fast‐growing	
CHE	and	M.	fortuitum	were	rapidly	cleared,	while	strains	of	the	slow‐growing	M.	
avium	 complex	multiplied	 to	 three	 logs	 above	 the	 other	 strains	 in	 the	 spleen,	
liver	and	lungs	(Brandt,	2002).		
	
Env	 can	 also	 induce	 immunosuppressive	 responses,	 as	 evidenced	 by	 studies	
where	 M.	 vaccae	 administration	 reduced	 airway	 inflammation	 and	 hyper‐
responsiveness	in	asthmatic	models	in	mice	(Hopfenspirger	and	Agrawal,	2002)	
and	guinea	pigs	(Zhao,	2003).	The	M.	vaccae	effect	is	not	due	to	a	switch	to	a	Th1	
dominated	 response	 as	 earlier	 thought	 (Zuany‐Amorim,	 2002a;	 Adams,	 2004).	
An	 IL‐10	 and	 TGF‐	 dependent	 CD4+CD45RBlo	 T	 cell	 population	was	 found	 to	
harbour	Treg	activity	as	the	adoptive	transfer	of	these	cells,	taken	from	M.	vaccae	
sensitised	 mice,	 into	 allergic	 recipient	 mice,	 blocked	 the	 response	 to	 airway	
challenge	with	antigen	in	these	mice	(Zuany‐Amorim,	2002a),	and	this	was	found	
to	be	allergen	specific	 (Zuany‐Amorim,	2002b).	Certain	strains	of	M.	avium	 are	





It	 has	 been	 proposed	 that	 exposure	 to	 Env	 through	 environmental	 contact	
results	 in	 immune	modulation	of	 the	 response	 to	BCG,	which	adversely	 affects	
the	 protection	 conferred.	 Numerous	 animal	 studies	 have	 long	 supported	 this	
notion	 (Edwards,	 1982;	 Orme	 and	 Collins,	 1986;	 Howard,	 2002).	 Human	
epidemiological	studies	also	show	that	BCG	is	more	efficacious	where	neonates	




exposure	on	BCG	vaccination.	The	 first	 is	 the	 ‘masking’	hypothesis	 –	prior	Env	
exposure	 confers	 a	 level	 of	 immune	 protection	 against	 TB,	 which	 masks	 the	
effects	of	 a	 subsequent	BCG	vaccination.	Guinea	pig	 studies	by	Palmer	 in	1966	
(Palmer	 and	 Long,	 1966)	 first	 noted	 that	 Env	 immunisation	 offers	 some	
protection	against	TB	challenge,	but	reduces	the	apparent	protection	conferred	
by	 BCG.	 Circumstantial	 evidence	 from	 human	 epidemiological	 studies	 also	
supports	this	hypothesis,	because	BCG	vaccine	efficacy	is	reduced	in	populations	
highly	 sensitised	 to	 Env	 (Black,	 2001a;	 Black,	 2002).	Much	 of	 such	 knowledge	
arises	from	studies	comparing	Malawi	and	United	Kingdom,	as	these	populations	
differ	markedly	in	BCG	efficacy	in	clinical	trials	(Sutherland	and	Springett,	1987;	
Group,	 1996).	 Prevalence	 and	 magnitude	 of	 skin‐test	 sensitivity	 to	 protein	
preparations	 derived	 from	 Env	 species	 are	 higher	 in	 Malawi	 than	 in	 the	 UK,	
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affirming	that	Malawians	have	greater	Env	exposure	(Black,	2001b;	Black,	2002;	
Weir,	 2003).	 In	 Malawians,	 BCG	 vaccination	 confers	 no	 additional	 protection	
relative	 to	unvaccinated	 controls,	 and	 their	post‐BCG	cellular	 responses	 (IFN‐γ	









A	 second	 hypothesis,	 the	 ‘blocking’	 hypothesis’,	 based	 on	 animal	 studies,	
suggests	 that	 prior	 Env	 sensitisation	modifies	 the	 host’s	 BCG	 response,	 which	




relative	 to	non‐sensitised	mice	 (Brandt,	2002).	This	occurs	even	 though	 the	M.	
avium	 is	 cleared	with	 antibiotics	 before	BCG	 administration.	Demangel’s	 study	
concurs	 that	 Env	 diminishes	 BCG	 replication,	 but	 differs	 in	 not	 observing	 any	





However,	 the	precise	 immune	mechanisms	underlying	 the	 cellular	 response	 to	
Env	 and	 how	 these	 led	 to	 reduced	 BCG	 replication	 is	 largely	 unknown.	 A	 few	
mechanistic	studies	have	emerged	in	recent	years.	One	study	has	proposed	that	
induction	of	Th2	responses	may	underlie	how	Env	modifies	 the	host	 response.	
Oral	 exposure	 to	M.	 avium	 reduces	 IFN‐	 responses	 and	 upregulates	 antibody	
responses	 in	BCG	vaccinated	mice,	 suggesting	 a	 switch	 to	Th2	 responses	upon	
Env	exposure	(Young,	2007).	Another	study	claims	that	DCs	exposed	to	M.	avium	
do	 not	 express	 co‐stimulatory	 molecules	 but	 upregulate	 programmed	 death‐1	




effect.	A	Gambian	neonatal	 study	shows	 that	delaying	BCG	vaccination	 for	4	½	
months	(allowing	time	for	Env	exposure)	leads	to	reduced	IFN‐,	IL‐6,	and	IL‐17	
responses	 (all	 of	 which	 have	 anti‐mycobacterial	 properties),	 relative	 to	
vaccination	at	birth,	but	both	groups	have	similar	anti‐mycobacterium	responses	
at	nine	months	(Burl,	2010).	The	IFN‐	reduction	is	not	directly	correlated	with	
pre‐vaccine	 natural	 Treg	 frequencies	 or	 IL‐10	 levels	 in	 the	 delayed	 vaccine	
group.	The	authors	suggest	that	low	levels	of	IL‐6	may	contribute	to	poorer	IL‐17	




is	 minimal.	 Does	 Env	 exposure	 after	 BCG	 vaccination	 have	 any	 effect	 on	 BCG	
efficacy?	 There	 is	 limited	 data,	 but	 a	murine	 study	 on	 oral	M.	avium	 exposure	
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following	 BCG	 vaccination	 shows	 this	 lowers	 the	 magnitude	 of	 Mtb	 load	
reduction	 in	 the	 lungs	 conferred	by	BCG	vaccination,	 unrelated	 to	 any	obvious	
changes	in	T	cell	immunity	(Flaherty,	2006).	Whether	the	effects	are	because	of	
live	M.	 avium	 colonising	 the	 lungs	 is	 unclear.	 In	 a	 human	 study	 focusing	 on	
delivering	BCG	vaccines	within	the	first	month	of	life,	there	is	still	a	substantially	
lower	proportion	of	Malawian	 infants	 (53%)	with	 IFN‐	 responses	 to	Mtb	PPD	
post‐vaccination,	as	compared	to	UK	infants	(100%)	(Lalor,	2009).	Although	the	
reasons	 for	 the	 difference	were	 not	 studied,	 exposure	 to	 Env	 after	 vaccination	
remains	one	of	the	possible	explanations.		
	
There	 are	 also	 papers	 that	 disagree	 that	 Env	 exposure	 is	 negative	 for	 BCG	
vaccination	responses.	One	study	states	that	cattle	exposure	of	cattle	to	M.	avium	
before	 BCG	 vaccination	 does	 not	 reduce	 BCG‐specific	 immune	 responses	 and	






(Brunkow,	2001;	Fontenot,	2003;	Sakaguchi	 and	Sakaguchi,	 2005).	 In	 addition,	
Tregs	are	important	in	limiting	harmful	inflammatory	responses,	as	observed	in	
allergic	disorders	(Zuany‐Amorim,	2002b),	inflammatory	bowel	disease	(Powrie,	
1994)	 and	 bacteria‐triggered	 colitis	 (Kullberg,	 2002).	 Tregs	 exert	 suppressive	
effects	on	 immune	responses,	 and	are	known	 to	 influence	CD4+	 (Thornton	and	
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Shevach,	2000),	CD8+	T	cells	(Piccirillo	and	Shevach,	2001;	Green,	2003)	as	well	
as	 cells	 of	 innate	 immunity	 (Maloy,	 2003).	 Tregs	 are	 hence	 an	 important	
consideration	when	evaluating	efficacy	of	 immune	responses	against	 infectious	







(Bluestone	 and	 Abbas,	 2003;	 O'Garra,	 2004).	 Based	 on	 murine	 models	 of	
inflammatory	 diseases	 such	 as	 cancer	 and	 autoimmune	 disorders,	 various	







known	 as	 IL‐2	 receptor	 –chain),	 and	 in	 some	 cases	 also	 the	 co‐stimulatory	
molecule	 cytotoxic	 T	 lymphocyte	 antigen	 4	 (CTLA‐4),	 tumour	 necrosis	 factor	
(TNF)‐superfamily	member	 glucocorticoid‐induced	 TNF	 receptor	 family	 related	





CD8+	 T	 cells	 (Thornton	 and	 Shevach,	 1998;	 Murakami,	 2002),	 and	 the	
transcription	factor	FoxP3	is	the	most	definitive	molecular	marker	for	these	cells,	
particularly	 in	mice	 (Fontenot,	 2003;	 Fontenot,	 2005;	 Roncador,	 2005),	 though	
FoxP3	is	also	transiently	upregulated	on	activated	human	T	cells	(Gavin,	2006).		
	






against	 the	parasite	 in	 the	same	model,	demonstrating	 the	 fine	balance	between	
the	 immune	 responses	 to	 the	 host	 and	 pathogen	 that	 is	 influenced	 by	 nTregs	
(Belkaid,	2002).	The	immunosuppression	exerted	by	nTregs	can	be	excessive	 in	
some	 instances,	 thereby	 allowing	 the	 pathogen	 to	 replicate	 aggressively	 and	
compromise	 the	 survival	 of	 the	 host.	 This	 is	 observed	 in	 mice	 infected	 with	
Plasmodium	yoelii,	which	causes	lethal	malaria	in	rodents.	nTreg	depletion	restores	
effector	 immune	 responses	 that	 are	 otherwise	 limited	 by	 nTregs,	 eventually	
leading	to	pathogen	elimination	and	host	survival	 (Hisaeda,	2004).	Self	antigens	
released	 during	 tissue	 damage	 in	 acute	 diseases	 are	 probably	 recognised	 by	
nTregs,	 priming	 their	 activity,	 but	 studies	 of	 chronic	 infections	 suggest	 that	
nTregs	 can	 also	 recognise	 microbial	 antigens	 (Belkaid,	 2002;	 Cabrera,	 2004;	
Weiss,	 2004;	 Hisaeda,	 2005).	 Furthermore,	 instead	 of	 being	 anergic,	 nTregs	
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proliferate	at	 the	 site	of	 infection	when	 they	encounter	microbial	 antigens,	and	





observed,	 together	with	 elevated	mRNA	 expression	 of	 FoxP3,	 in	 the	 peripheral	
blood	 of	 these	 patients	 (Guyot‐Revol,	 2006).	 The	 authors	 suggest	 that	 this	
expansion	of	Tregs	may	contribute	to	suppression	of	immune	responses	against	
TB.	 Other	 human	 and	 murine	 studies	 have	 also	 repeatedly	 demonstrated	 that	
CD4+CD25+	 Treg	 can	 be	 expanded	 and	 suppress	 T	 cell	 mediated	 protective	
responses	during	the	course	of	TB	disease,	thus	facilitating	pathogen	persistence	
(Dieckmann,	 2005;	 Hougardy,	 2007a;	 Mason,	 2007).	 A	 study	 on	 effects	 of	
reconstituting	 recombination	 activating	 gene	 (RAG)	 deficient	 mice,	 which	 lack	
functional	T	and	B	cells,	with	CD4+CD25+	Tregs	and	CD4+CD25‐	cells,	shows	that	
the	 Tregs	 directly	 restrict	 T	 helper	 cell	 proliferation,	 IFN‐	 production,	 and	
abrogate	the	protection	against	Mtb	challenge	conferred	by	T	helper	cells	(Kursar,	
2007).	 In	 support	 of	 this,	 human	 ex	 vivo	 peripheral	 blood	 experiments	 suggest	
that	 CD4+CD25+	 Tregs	 in	 TB	 patients	 suppress	 Th1	 but	 not	 Th17	 cells	 (Marin,	
2010).	Both	these	studies	suggest	that	the	effects	of	these	CD4+CD25+	Tregs	are	
not	 due	 to	 IL‐10.	 The	 suppression	 of	 immunity	 against	 TB	 mediated	 by	
CD4+CD25+FoxP3+	 Tregs	 is	 also	 independent	 of	 IL‐10	 (Chen,	 2007),	 suggesting	










develop	 after	 encountering	 antigen	 presenting	 cells	 modulated	 by	 microbial	
antigens	or	upon	contact	with	regulatory	cytokines	 (O'Garra,	2004).	Activity	of	
antigen‐driven	 iTregs	 may	 not	 require	 FoxP3	 (Vieira,	 2004),	 and	 instead	
requires	 the	 immunoregulatory	 cytokines	 IL‐10	 and	TGF‐β	 (Groux,	 1997).	 The	
ability	 of	 IL‐10	 to	 inhibit	 both	 Th1	 and	 Th2	 responses	 has	 been	 shown	 in	
experimental	 models	 of	 various	 chronic	 diseases	 such	 as	 malaria	 and	




individuals	 latently	 infected	 with	 TB,	 but	 not	 non‐infected	 individuals	 in	 the	
presence	 of	 TGF‐	 and	 BCG	 (Hougardy,	 2007b),	 indicating	 that	 Tregs	 can	 be	
induced	in	TB	infected	patients.	This	is	important	in	controlling	effector	immune	
responses	 beneficial	 to	 the	 host,	 as	 observed	 in	murine	models	 of	Toxoplasma	
gondii,	 where	 IL‐10	 deficient	mice,	 although	 able	 to	 control	 parasite	 numbers,	




the	presence	of	 different	 stimuli,	 including	TGF‐	 upon	T	 cell	 receptor	 ligation	
(Chen,	 2003;	 Fantini,	 2004;	 Zheng,	 2007),	 IFN‐	 (Wang,	 2006)	 and	 prolonged	
exposure	 to	 low	 dose	 antigens	 (Kretschmer,	 2005).	 Peripheral	 conversion	 of	
Tregs	 is	potentially	 important	 in	 long‐term	chronic	 infectious	diseases,	 such	as	
TB,	as	the	output	of	nTregs	is	expected	to	diminish	with	ageing,	due	to	a	reduced	
production	 of	 T	 cells	 over	 time	 in	 the	 face	 of	 chronic	 antigenic	 stimulation	




Monocytes	 and	macrophages	 are	 rapidly	 induced	 to	produce	 IL‐10	during	Mtb	
infections	 (Song,	 2003),	 and	 T	 cells	 can	 also	 produce	 IL‐10	 upon	 stimulation	
(Boussiotis,	 2000).	 IL‐10	 mediates	 suppression	 of	 immune	 responses	 during	
active	 TB,	 which	 includes	 suppressing	 the	 production	 of	 proinflammatory	
cytokines	 like	 IFN‐	 and	 TNF‐	 (Fiorentino,	 1991;	 Gong,	 1996;	 Hirsch,	 1999),	
impairing	 Th1	 responses	 (Akbari,	 2001)	 and	 directing	 responses	 towards	 the	
Th2	type	in	the	lungs	of	infected	hosts	(Almeida,	2009),	regulating	macrophage	
apoptosis	 (Patel,	 2009),	 inhibiting	 the	 differentiation	 of	 monocytes	 to	 DCs	









may	 confer	 some	 immune	 protection	 against	 TB,	 masking	 the	 effects	 of	
subsequent	 BCG	 vaccination.	 This	 was	 later	 also	 supported	 by	 circumstantial	
evidence	 from	 human	 studies	 in	 Malawi.	 The	 population	 had	 high	 levels	 of	
immune	 recognition	 of	 Env	 antigens	 before	 vaccination	 (Black,	 2001a),	 and	
subsequent	 BCG	 vaccination	 conferred	 little	 additional	 protection	 against	 TB	
relative	to	non‐vaccinated	controls	(Ponnighaus,	1992).	The	above	observations	
suggest	 that	 although	 Env‐induced	 symptomatic	 disease	 is	 uncommon	 in	
humans,	exposure	to	Env	may	nonetheless	prime	T	cell	memory	responses	that	
influence	 the	 subsequent	 response	 to	 BCG.	 However,	 effector	 mechanisms	 of	
Env‐specific	T	cells	have	not	been	fully	elucidated.	In	murine	studies,	prior	Env	
exposure	 limits	 the	 survival	 of	 live	 BCG	 given	 subsequently	 (Brandt,	 2002;	
Demangel,	 2005).	 This	 may	 be	 due	 to	 cross‐reactive	 memory	 responses	 to	
shared	 antigens,	 but	 the	 nature	 of	 Env‐induced	 effector	 cells	 and	 how	 they	
interact	 subsequently	 with	 BCG‐infected	 cells,	 were	 not	 described	 in	 those	
studies.	
	
There	 is	 evidence	 for	 human	 T	 cells	 with	 Mycobacterium‐specific	 cytotoxic	




hypothesised	 that	 the	 curtailment	of	BCG	survival	 after	Env	exposure	 could	be	
due	to	cytotoxicity	against	 live	BCG	and/or	BCG‐infected	cells,	 induced	by	Env‐
specific	 memory	 cells	 that	 recognise	 shared	 (common)	 antigens	 between	 BCG	
and	Env.	This	work	also	sought	to	identify	some	cells	types	and	factors	that	may	
play	a	 role	 in	 this	Env‐induced	cytotoxicity.	The	data	 showed	 that	CD4+	T	cells	
from	 CHE‐sensitised	 mice,	 but	 not	 naïve	 mice,	 kill	 BCG‐infected	 autologous	
macrophages	 and	 that	 IFN‐γ,	 perforin	 and	 FasL	 may	 have	 a	 role	 in	 the	
cytotoxicity.	 The	 sensitisation	 also	 resulted	 in	 increased	 cellular	 responses	 to	












M.	 chelonae	 (CHE)	derived	 from	 clinical	 samples,	was	 a	 kind	 gift	 from	Dr	 Pam	
Nye,	 University	 College	 London	 Hospitals	 (UK).	 Mycobacterium	 bovis	 BCG	
(Pasteur)	 vaccine	 strain	was	 donated	by	Dr	William	 Jacobs,	 Jr	 (Albert	 Einstein	
College	 of	 Medicine,	 USA).	 All	 species	 were	 subsequently	 cultivated	 on	
Middlebrook	 7H10	 agar	 (refer	 to	 appendix),	 supplemented	 with	 oleic	 acid‐
albumin‐dextrose‐catalase	(OADC;	Difco),	and	single	colonies	picked	for	growing	
in	Middlebrook	7H9	broth	(Difco)	+	0.1	%	Tween	80	(refer	to	appendix).	Bacillus	






min	 and	 washed	 twice	 with	 sterile	 phosphate	 buffered	 saline	 (PBS,	 prepared	
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with	 nanopure	 water)	 before	 re‐suspension	 in	 PBS.	 This	 bacterial	 suspension	
was	syringed	through	a	27	G	needle	to	reduce	clumping,	before	absorbance	was	
measured	 at	 600	 nm	 to	 estimate	 bacterial	 numbers	 (1	 A600	 ~	 1.25	 x	 108	
bacteria).	Bacterial	suspensions	were	diluted	to	obtain	1	x	106	cells/	100	μl	PBS	
or	 1	 x	 107	 cells/	 50	 μl	 PBS	 for	 murine	 immunisation	 and	 lymphocyte	
restimulation	 respectively.	 For	 heat‐killed	 preparations,	 these	 aliquots	 were	
treated	at	95C	 for	15	min,	 all	 in	one	batch	 to	ensure	uniformity	of	 treatment,	
then	 snap‐frozen	 until	 use.	 For	 intra‐nasal	 (i.n.)	 infection	 of	mice,	 1	 x	 105	 live	
BCG	were	re‐suspended	in	a	final	volume	of	10	μl	PBS.	Such	preparations	were	
kept	 at	 37	 C	 prior	 to	 infection.	 All	 bacterial	 preparations	 were	 subjected	 to	
purity	 check	 and	 counting	 of	 the	 actual	 colony‐forming	 units	 (CFU)	 by	 serial	
dilutions	 and	 culture	 on	 solid	 media.	 BCG,	 CHE	 and	 B.	 subtilis	 colonies	 were	





weeks,	 with	 PBS	 or	 106	 heat‐killed	 CHE	 in	 100	 μl	 sterile	 PBS,	 prepared	 as	







macrophages	 were	 harvested	 by	 injecting	 10	 ml	 of	 ice‐cold	 RPMI	 1640	
supplemented	with	2	mM	L‐glutamine	(RPMI,	Sigma)	+	10	%	fetal	bovine	serum	
(FBS,	BioGen)	 into	 the	peritoneal	 cavity	 via	 a	21	G	needle	 and	 the	peritoneum	
gently	massaged	before	withdrawal	of	the	peritoneal	fluid	through	a	18	G	needle.	
All	 peritoneal	 fluid	 was	 subsequently	 kept	 on	 ice,	 until	 use.	 Cell	 suspensions	
were	centrifuged	at	400	x	g	at	4C,	for	10	min,	and	cells	re‐suspended	in	2	ml	of	




Lung	 tissue	 was	 subjected	 to	 enzymatic	 digestion	 in	 1	 ml	 of	 0.34	 PZ‐U/	 ml	










B	 cells	were	 depleted	 from	 splenocytes	 using	 Dynabeads	Mouse	 pan	B	 (B220;	
Dynal	Biotech	ASA,	Oslo,	Norway)	at	1	bead:	1	splenocyte	ratio.	According	to	the	
manufacturer’s	 instructions,	 briefly,	 splenocytes	 were	 labelled	 with	 anti‐CD19	
linked	to	magnetic	beads,	 in	RPMI	+	5	%	FBS	for	30	min	at	4	C.	After	negative	
magnetic	selection,	a	portion	of	the	B	cell‐depleted	splenocytes	were	seeded	at	2	
x	 106	 cells/	 ml	 of	 RPMI	 +	 5	 %	 FBS	 in	 a	 24‐well	 plate	 (Greiner)	 for	 antigen	
restimulation	 while	 the	 remaining	 B	 cell‐depleted	 splenocytes	 underwent	





with	 10	 μl	 of	 cell	 suspension.	 Cells	 were	 then	 counted	 under	 the	 microscope	






the	 CD4+	 positive	 selection	 MACS	 kit	 (Miltenyi	 Biotec).	 Splenocytes	 were	
incubated	 in	 staining	 buffer,	 with	 CD4‐specific	 antibodies	 coupled	 to	 magnetic	
beads	 at	 4	 C	 for	 15	min	 in	 the	 dark,	 according	 to	manufacturer’s	 instructions.	
Following	 processing	 through	 the	 autoMACS	 (automated	Magnetic	 Cell	 Sorting;	
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Miltenyi	 Biotec)	 column,	 magnetically‐labelled	 cells	 were	 separated	 from	 non‐
labelled	cells	using	the	‘positive	selection’	mode.	The	labelled	and	non‐labelled	cells	
were	collected	from	the	positive	and	negative	ports	respectively,	in	5	ml	of	RPMI	+	





cells/	 ml	 in	 each	 well	 of	 a	 24–well	 plate	 for	 re‐stimulation.	 After	 48	 h	 of	
stimulation	with	heat‐killed	CHE,	supernatants	harvested	from	cell	cultures	were	
assayed	 by	 Enzyme‐Linked	 Immunosorbent	 Assay	 (ELISA)	 for	 the	 presence	 of	
IFN‐	 and	 IL‐10	 (R&D	 Systems),	 using	 the	 respective	 kits	 according	 to	
manufacturer’s	 instructions.	 All	 assays	 were	 based	 on	 the	 sandwich	 ELISA.	 In	
brief,	ELISA	plate	(Co‐star	or	BD	Falcon)	wells	were	coated	with	diluted	cytokine‐
specific	 capture	 antibody	 overnight,	 blocked	 using	 assay	 diluent,	 and	
subsequently	 incubated	 with	 culture	 supernatant	 or	 diluted	 recombinant	
cytokine	 standards.	 Biotinylated	 antibodies	 specific	 for	 the	 respective	 cytokines	
were	 used	 for	 detection,	 and	 streptavidin‐	 or	 avidin‐	 horse	 radish	 peroxidase	
(HRP)	were	 used	 in	 conjunction	with	 TMB	 substrate	 to	 produce	 a	 colorimetric	
change.	The	absorbance	was	read	at	450	nm	with	a	correction	wavelength	of	570	






mediated	 cytotoxic	 responses	 following	 antigen	 stimulation.	 The	 CytoTox	 96®	
Non‐radioactive	 Assay	 is	 a	 colorimetric	 assay	 that	 quantitatively	 measures	 a	
stable	cytosolic	enzyme	–	lactate	dehydrogenase	(LDH),	which	is	released	upon	










Freshly	 isolated	 murine	 peritoneal	 cells	 were	 seeded	 in	 triplicates	 in	 96‐well	
round‐bottom	tissue	culture	plates	at	2	x	104	macrophages	per	200	ml	of	RPMI	+	
10	%	FBS.	The	adherent	cells,	 after	overnight	 culture,	were	used	as	 target	 cells.	
Separately,	 to	 generate	 effector	 cells,	 CD4+,	 CD4‐	 and	 total	 B‐cell	 depleted	




ratio	 of	 10:1)	 or	 PBS,	 non‐adherent	 effector	 cells	 were	 harvested	 for	 viability	
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count,	 and	 the	 culture	 media	 replaced	 with	 fresh	 RPMI	 without	 phenol	 red	








between	 the	 effector	 cells	 and	 target	 macrophages.	 In	 some	 experiments,	
endotoxin‐free	 Ab	 –	 anti‐IFN‐10	 g/	ml,	 XMG1.2;	 BioLegend),	 anti‐IL‐10	 (10	




was	 again	 centrifuged	 at	 250	 x	g	 for	 4	min	 to	 obtain	 the	 cell‐free	 supernatant.	
Certain	control	wells	were	also	set	up	–	effector	cells	added	to	wells	without	target	
cells	 (‘Effector	 Spontaneous’),	 target	 cells	 without	 effector	 cells	 (‘Target	




bottom	non‐sterile	plates	 and	50	l	 of	 reconstituted	 substrate	mixture	 from	 the	
assay	 kit	 was	 added	 to	 each	well	 for	 30	min	 at	 room	 temperature	 in	 the	 dark.	
Thereafter,	 50	 l	 of	 stop	 solution	 was	 added.	 Intensity	 of	 colour	 change	 in	
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individual	wells	was	measured	using	 the	Magellan	ELISA	Reader	(Tecan)	at	490	








with	 relevant	 mAb	 or	 isotype	 controls	 in	 staining	 buffer	 for	 30	 min	 on	 ice,	
washed	with	cold	PBS,	 then	ﬁxed	with	4%	paraformaldehyde.	For	 intracellular	
perforin	and	IFN‐	staining,	the	cells	were	permeabilised	by	washing	with	0.1%	






were	 used,	 along	 with	 their	 respective	 isotype	 controls:	 CD3	 (145‐2C11,	 BD	










Splenocytes	 from	 naïve	 mice	 sensitised	 by	 intra‐peritoneal	 (i.p.)	 immunisation	
with	 heat‐killed	 M.	 avium,	 CHE,	 M.	 smegmatis,	 BCG	 or	 PBS,	 exert	 a	 range	 of	
cytotoxic	 responses	 against	 BCG‐infected	 autologous	 macrophages	 upon	
stimulation	with	different	heat‐killed	mycobacterial	preparations	(Ho,	2009).	CHE	
sensitisation	 in	 vivo,	 followed	 by	 in	 vitro	 splenocyte	 restimulation	 with	
Mycobacterium	antigens,	resulted	in	the	strongest	cytotoxicity	compared	to	other	
Env‐sensitised	 mice.	 This	 is	 why	 CHE	 sensitisation	 was	 chosen	 in	 the	 present	




The	most	 likely	explanation	 is	 that	 the	enhanced	cytotoxicity	 is	due	 to	memory	




Earlier	 studies	 in	 the	 laboratory	 have	 shown	 that	 if	 CD4+	 cells	 were	 depleted	
from	 lymphocytes	 of	 CHE‐sensitised	mice	 before	 co‐culture	 with	 BCG‐infected	
cells,	 cytotoxicity	 is	 almost	 completely	 inhibited	 relative	 to	 untouched	





cytotoxicity	 against	 BCG,	 the	 cytotoxicity	 assay	was	 repeated	with	 either	 pure	
CD4+	 cells	 or	 CD4‐depleted	 T	 cells	 (CD4‐)	 (Fig.	 3.2).	 Antigen‐stimulated	 CD4+	
cells	 in	 co‐cultures	with	 autologous	 BCG‐infected	macrophages	 showed	 higher	
cytotoxicity	than	co‐cultures	with	CD4‐	cells	(p	=	0.07),	supporting	the	previous	
results	and	providing	direct	evidence	 for	 the	role	of	CD4+	cells	 in	CHE‐induced	
cytotoxicity.	The	cytotoxicity	induced	by	cells	of	CHE‐sensitised	mice	was	higher	
than	 that	 by	 cells	 from	 PBS	 control	mice,	 regardless	 of	 which	 T	 cell	 type	was	
used.	
	
To	 confirm	 that	 cytotoxicity	 of	 infected	macrophages	 is	 linked	 to	 killing	 of	 the	
intracellular	 bacteria,	 BCG	 in	 the	 wells	 were	 cultured	 at	 the	 end	 of	 the	
cytotoxicity	 assay.	 There	 was	 a	 significant	 negative	 correlation	 between	 %	
cytotoxicity	 and	 viable	 BCG	 counts,	 suggesting	 that	 the	 lysis	 of	 infected	



















their	 splenocytes	 harvested.	 CD4+	 positively	 selected	 cells	 (by	 autoMACS)	 and	
CD4‐	 cells	 (negative	 fraction	 after	 CD4	 selection)	 from	 the	 splenocytes	 were	
stimulated	with	heat‐killed	CHE	or	PBS	and	then	co‐cultured	with	BCG‐infected	





Various	 factors	 were	 neutralised	 using	 inhibitors	 prior	 to	 performing	 the	
cytotoxicity	 assay	 in	 CHE‐sensitised	mice,	 to	 investigate	 some	 of	 the	 potential	
pathways	and	cytokine	mediators	involved	in	CHE‐induced	cytotoxicity.	Blocking	
either	 FasL	 or	 perforin	 pathways	 led	 to	 reduced	 cytotoxicity,	with	 a	 relatively	
greater	 reduction	 seen	when	perforin	was	blocked.	When	both	pathways	were	
concurrently	 inhibited,	 the	 mean	 cytotoxicity	 was	 further	 reduced	 but	 not	
significantly	 more	 than	 either	 pathway	 alone	 (Fig.	 3.3A).	 Inhibition	 of	 IFN‐	
significantly	 reduced	 cytotoxicity	 (Fig.	 3.3B),	 but	 there	 was	 no	 effect	 upon	
blocking	 IL‐10	 (Fig.	 3.3B).	 Thus	 Fas,	 perforin	 and	 IFN‐,	 play	 a	 role	 in	 CHE‐





and	 not	 a	 result	 of	 non‐specific	 inflammatory	 responses,	 naïve	 mice	 were	
sensitised	 with	 an	 unrelated	 bacterium	 Bacillus	 subtilis,	 and	 cytotoxicity	 of	
splenocytes	 from	 these	 mice	 were	 compared	 against	 that	 of	 cells	 from	 CHE‐
sensitised	 mice.	 Regardless	 of	 the	 in	 vitro	 stimulation,	 splenocytes	 from	 B.	
subtilis	 sensitised	 mice	 exerted	 cytotoxic	 effects	 that	 were	 similar	 to	 negative	
control	mice	given	PBS	–	significantly	less	than	the	cytotoxicity	observed	in	co‐
cultures	 of	 cells	 from	 CHE‐sensitised	 mice	 (Fig.	 3.4)	 This	 implies	 that	








Mice	were	 i.p.	 immunised	with	 heat‐killed	 CHE	 three	 times,	 once	 a	week,	 and	
splenic	T	cells	were	re‐stimulated	in	vitro	with	heat‐killed	CHE	before	co‐culture	
with	BCG‐infected	macrophages	 to	 test	 for	cytotoxicity.	Prior	 to	and	during	co‐

















Perforin	 expression	 is	 a	 marker	 of	 cells	 with	 cytotoxic	 potential.	 After	 BCG	
infection,	CD4+	 cells	 accounted	 for	almost	70%	of	 the	perforin‐positive	 cells	 in	
both	 CHE‐	 and	 PBS‐sensitised	mice,	 indicating	 the	 predominance	 of	 CD4+	 cells	
among	 perforin‐expressing	 cells	 (Fig.	 3.5A).	 A	 mean	 of	 18.6%	 of	 CD4+	 cells	
expressed	 perforin,	 while	 only	 a	 mean	 of	 3.5%	 of	 CD8+	 cells	 were	 perforin‐
positive,	demonstrating	that	a	higher	proportion	of	CD4+	cells,	compared	to	CD8+	
cells,	 harboured	 the	 cytotoxic	 perforin	 (Fig.	 3.5B).	 However,	 there	 was	 no	
differential	perforin	expression	between	sensitised	and	control	mice.	
	
Of	 all	 the	 IFN‐	 producing	 cells	 in	 the	 lungs,	 CD4+	 cells	were	 the	 predominant	
subset,	significantly	more	than	CD8+	cells	(Fig.	3.5C).	Within	both	CD4+	and	CD8+	
populations,	 a	 higher	 percentage	 of	 cells	 producing	 IFN‐	 was	 observed	 in	
sensitised	 compared	 to	 non‐sensitised	 mice	 (Fig.	 3.5D).	 	 Post‐BCG	 infection,	




To	 determine	 the	 effects	 of	 CHE	 on	 BCG	 survival	 in	 vivo,	 mice	 sensitised	with	
heat‐killed	 CHE	 or	 PBS	were	 challenged	with	 live	 BCG	 intra‐nasally	 one	week	
after	 the	 last	 immunisation,	 and	 BCG	 load	 in	 the	 lung	 examined	 either	 one	 or	
three	 weeks	 after	 BCG	 infection.	 Bacterial	 load	 was	 assayed	 in	 the	 lungs	 by	
measuring	colony‐forming	units	(CFU).	Lung	BCG	counts	in	sensitised	mice	were	
2‐	 and	 6‐fold	 lower	 than	 PBS	 mice	 at	 one	 and	 three	 weeks	 post‐infection	
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Lung	 single‐cell	 suspensions	 from	 CHE‐immunised	 and	 PBS‐control	 mice,	 one	
week	after	BCG	infection	 in	vivo,	were	analysed	by	flow	cytometry.	(A)	Perforin‐
positive	 cells	were	 gated	 and	percentages	 expressing	 CD4	or	 CD8	 assessed.	 (B)	
Cells	were	gated	on	either	CD4+	or	CD8+	cells,	%	perforin‐positive	cells	shown.	(C)	
CD3+	 IFN‐	 positive	 cells	 were	 gated,	 and	 percentages	 expressing	 CD4	 or	 CD8	
assessed.	 (D)	 CD3+CD4+	 or	 CD3+CD8+	 cells	 were	 gated,	 percentage	 of	 IFN‐	





















describe	 a	 particular	 role	 of	 Env	 sensitisation	 in	 inducing	 cytotoxicity	 against	





cells	 (Mustafa	 and	 Godal,	 1987;	 Hancock,	 1989;	 Boom,	 1991;	 Lorgat,	 1992;	
Pithie,	 1992;	 Silva	 and	 Lowrie,	 2000;	 Boselli,	 2007).	 Peripheral	 blood	 CD4+	 T	
cells	of	active	TB	patients	display	cytotoxicity	against	Mtb‐infected	macrophages,	
which	 decreases	 with	 severity	 of	 TB	 (De	 La	 Barrera,	 2003).	 CD8+	 T	 cells,	
however,	remain	the	most	widely	reported	cell	type	exerting	cytotoxic	effects	in	
TB	(Sousa,	2000;	Sada‐Ovalle,	2006;	Billeskov,	2007)	and	are	known	to	harbour	
cytotoxic	 precursors	 such	 as	 granulysin	 and	 perforin	 (Stenger,	 1998;	
Stegelmann,	 2005).	 CD8+	 CTL	 activity	 is	 reduced	 in	 TB	 patients	 compared	 to	
healthy	controls	(Smith,	2000),	suggesting	that	the	 lack	of	such	activity	may	be	
related	to	disease.	In	murine	studies,	experiments	with	2	microglobulin	or	MHC	
Class	 I	 gene‐deleted	 mice	 suggest	 that	 CD8+	 T	 cells	 are	 required	 for	 Mtb	
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cells	 has	 no	 effect	 on	 bacteria	 numbers	 (Bermudez	 and	 Petrofsky,	 1999),	
whereas	 in	wild‐type	mice,	 infection	 is	worse	 and	 lung	 cytotoxicity	 is	 reduced	
upon	depletion	of	CD4+,	but	not	CD8+	cells	 (Orme,	1992;	Saunders	and	Cheers,	
1995).	This	 supports	 the	present	 finding	 that	CHE	exposure	 induces	 functional	
CD4+	 T	 cells	 with	 cytotoxic	 activity.	 	 Lazarevic	 noted	 that	 CD8+	 T	 cells	 are	
cytotoxic	mainly	in	acute	TB	infection	and	cytotoxicity	diminishes	after	exposure	
to	high	doses	of	mycobacterial	antigens	for	prolonged	periods	(Lazarevic,	2005).	





cells	 can	 be	 FasL‐dependent	 or	 FasL‐independent	 (Lewinsohn,	 1998;	 Oddo,	
1998;	 Boselli,	 2007).	 Cytotoxic	 CD4+	 T	 cell	 clones	 derived	 from	 Mtb‐infected	
mice	lyse	target	cells	via	the	Fas‐FasL	pathway	(Silva	and	Lowrie,	2000).	Human	
studies	 suggest	 that	 cytotoxicity	of	CD4+	 and	CD8+	T	 cells	 against	Mtb‐infected	
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1997)	 –	 however,	 those	 studies	 did	 not	 specifically	 show	whether	 cytotoxicity	
was	 impaired	 in	 the	 mutant	 mice;	 possibly	 some	 redundancy	 in	 cytotoxic	




There	 are	 reports	 that	 infected	 macrophage	 lysis	 can	 be	 associated	 with	
Mycobacterium	 killing	 (Stenger,	 1998;	 Cho,	 2000;	 Thoma‐Uszynski,	 2000),	 but	
others	suggest	 that	human	Mycobacterium‐specific	CD4+	T	cell	 clones,	although	
able	 to	 lyse	 BCG‐infected	 cells,	 may	 not	 reduce	 BCG	 viability	 (Fazal,	 1995;	
Canaday,	2001).	Our	laboratory	has	demonstrated	in	vitro	that	%	cytotoxicity	in	
our	research	model	is	inversely	correlated	with	the	viable	BCG	count	(Ho,	2009),	
thereby	 supporting	 the	 probability	 that	 Env‐mediated	 cytotoxicity	 kills	 the	
intracellular	 BCG.	 Activated	 CD8+	 CTLs	 can	 certainly	 lyse	 Mtb	 directly	 using	
cytotoxic	 granules	 such	 as	 pore‐forming	 perforin	 and	 antibacterial	 granulysin	
(Stenger,	 1998).	 However,	 evidence	 on	 whether	 FasL	 or	 perforin	 mediated	





infection,	FasL	but	not	perforin	 is	 important	 in	 limiting	Mycobacterium	 load.	 	A	
study	 on	 cytotoxic	 effects	 of	 human	 Vgamma9/Vdelta2	 T	 lymphocytes	 (Dieli,	
2000)	 shows	 that	 perforin	 plays	 an	 important	 role	 in	 killing	 of	 both	 infected	







and	CD8+	 cytotoxic	T	 lymphocytes	 on	Mtb‐pulsed	macrophages	 (de	 la	Barrera,	
2004).	In	the	same	study,	Ab	neutralisation	of	endogenous	IL‐10,	as	well	as	the	
addition	of	 exogenous	 IFN‐	 to	CD4+	or	CD8+	 cells,	 increased	 cytotoxicity.	 FasL	
expression	on	human	CD4+	T	cells	is	regulated	by	IFN‐,	and	lowered	expression	
of	 FasL	 results	 in	 reduced	 CD4+	 CTL	 activity	 against	 mycobacteria	 (Boselli,	
2007).	IFN‐	depletion	reduces	cytotoxicity	in	M.		avium‐infected	mice	(Saunders	
and	Cheers,	1995).	Similarly,	this	study	found	that	CHE‐induced	cytotoxicity	was	





CD4+	 cells	 constituted	 the	 significant	 majority	 of	 IFN‐	 producing	 cells	 in	 the	











Prior	 papers	by	Brandt	 (Brandt,	 2002)	 and	Demangel	 (Demangel,	 2005)	 agree	
with	 our	 observations	 that	 different	 Env	 species	 have	 different	 effects	 on	 the	
subsequent	 BCG	 response.	 They	 suggest	 that	 cross	 recognition	 of	 antigens	
shared	 between	 Env	 and	 BCG	 underlies	 these	 effects.	 Brandt	 finds	 that	 pre‐




antigens	were	 used	 for	 sensitisation	 in	 this	 study.	We	 recognise	 that	 live	 Env	




processed,	 non‐viable	 CHE	preparation	was	 chosen	 for	 all	 assays	 in	 this	 study	
due	to	the	need	for	optimal	consistency	in	reproducing	the	Env	antigen	 load	in	
all	sensitised	mice,	because	antigen	load	critically	determines	the	CTL	response	
(Lazarevic,	 2005).	 In	 accordance	 with	 Brown	 (Brown,	 1985),	 this	 project	
hypothesised	 that	 the	 dose,	 route	 and	 timing	 of	 Env	 administration,	 the	
species/strain	used,	and	usage	of	live	or	dead	Env,	all	significantly	influence	the	
nature	 of	 the	 primary	 response	 and	 consequently,	 the	 extent	 to	 which	 Env	
exposure	enhances,	masks	or	interferes	with	effects	of	BCG.	Therefore,	in	further	




The	 ability	 of	 the	 Env	 species	 and	 BCG	 to	 colonise	 the	 host	 is	 a	 critical	
determinant	of	their	combined	immune	effects	(Brandt,	2002;	Young,	2007).	 In	
Demangel’s	study,	pre‐sensitisation	with	M.	avium	decreases	BCG	specific	 IFN‐	
responses	 and	 inhibits	 BCG	 growth;	 but	 under	 conditions	 of	 Env	 sensitisation	
that	still	allow	a	minimum	persistence	of	BCG,	 the	BCG	response	can	boost	 the	
Env‐induced	 primary	 response	 and	 improve	 protection	 against	 TB	 (Demangel,	
2005).	This	is	consistent	with	observations	in	this	study	that	after	BCG	challenge,	
IFN‐	responses	to	BCG	were	increased	in	CHE‐sensitised	mice,	relative	to	non‐





The	 present	 findings	 on	 the	 cytotoxicity	 against	 BCG	 induced	 by	 Env	
sensitisation	provide	a	novel	explanation	 for	 the	 limited	BCG	efficacy	 following	
Env	 exposure.	 This	 study	 accepts	 that	 there	 may	 be	 other	 explanations;	 for	
example,	some	believe	that	the	Env	effect	consists	of	Th2‐mediated	suppression	
of	BCG‐induced	responses,	associated	with	reduced	IFN‐	responses	to	BCG	after	
BCG	 challenge	 (Young,	 2007).	 Another	 important	 area	 for	 research	 is	 on	




implications	 for	 the	 next	 generation	 of	 TB	 vaccines	 (Andersen	 and	 Doherty,	
2005),	 in	 particular	 those	 involving	 live	 BCG,	 if	 they	 are	 to	 be	 used	 in	 areas	
where	 Env	 exposure	 is	 prevalent.	 Identification	 of	 vaccines	 which	 are	 not	
affected	 by	 prior	 Env	 sensitisation	 (Brandt,	 2002;	 Demangel,	 2005),	 or	 could	
even	boost	responses	to	primary	Env	exposure,	should	be	a	priority.			
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and	 India	 where	 the	 vaccine	 is	 most	 needed	 (Colditz,	 1995;	 Fine,	 1995).	 One	
possible	reason	 is	 that	prior	exposure	to	other	non‐tuberculous	species	of	Env,	
which	 is	 common	 in	 the	 tropics,	has	a	 role	 in	 this	phenomenon	(Colditz,	1995;	
Fine,	 1995).	Consistent	with	 this	 theory,	 individuals	 living	 in	 a	 rural	district	 of	
Malawi,	 where	 BCG	 provides	 little	 protection,	 have	 considerable	 exposure	 to	
Env,	 whereas	 BCG	 efficacy	 is	 high	 in	 the	 UK	 where	 such	 sensitisation	 is	 less	
evident	(Black,	2001a).	Moreover,	BCG	is	consistently	efficient	 in	 ‘clean’	animal	
models	 of	 TB	 (Smith,	 1985),	 as	well	 as	 in	 protecting	 newborns	 (without	 prior	
exposure	 to	 Env)	 against	 childhood	 manifestations	 of	 tuberculosis	 (Colditz,	










evidence	 from	 this	 study	 showed	 that	CHE	 sensitisation	 led	 to	 enhanced	 IL‐10	
and	 reduced	 inflammatory	 responses	 to	 BCG	 in	 vitro.	 CD4+CD25+	 Tregs	 have	
been	described	to	suppress	human	and	murine	responses	 to	BCG	(Jaron,	2008;	
Wammes,	 2010).	 This	 study	 found	 that	 CD4+CD25+	 Tregs	 induced	 by	 CHE	
sensitisation,	when	adoptively	transferred	in	vivo,	suppressed	the	inflammatory	







protocols	 approved	 by	 the	 NUS	 Institutional	 Animal	 Care	 and	 Use	 Committee	




administered	 with	 one	 million	 live	 BCG	 cells	 suspended	 in	 10	 μl	 PBS.	 After	












targeting	 CD8+	 T	 cells,	 B	 cells,	macrophages,	 NK	 cells	 and	 erythrocytes.	 CD25+	
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cells	were	 then	positively	selected	using	PE‐labelled	anti‐CD25	(7D4)	and	anti‐







CHE‐sensitised	 mice	 –	 were	 stained	 with	 CellTrace	 Far	 Red	 DDAO‐SE	
(Invitrogen).	 The	 CFSE‐stained	 cells	 were	 co‐cultured	 with	 the	 DDAO‐stained	
cells	 at	 a	 1:5	 ratio	 in	 96‐well	 plates.	 To	 perform	 the	 cell	 staining,	 two	 to	 five	
million	cells	were	incubated	with	either	10	M	CFSE	or	20	M	CellTrace	Far	Red	
DDAO‐SE	in	RPMI	containing	5	%	FBS	for	15	min	at	37	˚C	in	the	dark.	Cells	were	





BCG	per	 cell)	 for	 48	h	 before	 analysis	 of	 CFSE	 fluorescence	 by	 flow	 cytometry	
and	 assay	 of	 IFN‐γ	 production	 in	 the	 supernatants,	 respectively.	 By	 flow	














ELISA	 Set	 (BD	 Pharmingen)	 were	 used	 to	 evaluate	 the	 cytokine	 levels	 in	
supernatants	of	cell	cultures	and	BAL	fluid.	Cytokine	levels	were	measured	based	





BSA,	 then	stained	with	relevant	 fluorochrome‐conjugated	antibodies	at	4	 ˚C	 for	
30	 min	 in	 the	 dark	 and	 fixed	 with	 4	 %	 paraformaldehyde	 before	 use.	 For	
intracellular	 staining,	 cells	 were	 permeabilised	 with	 PBS	 containing	 0.1	 %	
saponin	(Sigma)	after	fixing,	then	blocked	with	PBS	containing	0.5%	BSA	and	0.1	
%	 saponin	 for	 30	 min	 at	 4	 ˚C,	 before	 staining	 with	 relevant	 antibodies.	 The	















To	 investigate	 whether	 CHE	 sensitisation	 modulates	 systemic	 cytokine	
production,	 levels	 of	 the	 pro‐inflammatory	 cytokine,	 IFN‐γ,	 and	 anti‐
inflammatory	 cytokine,	 IL‐10,	were	measured	 from	heat‐killed	 CHE‐stimulated	
splenocyte	 cultures.	 One	 week	 after	 the	 last	 CHE	 exposure,	 total	 splenocyte	
cultures	 from	CHE‐sensitised	mice	 contained	 significantly	 less	 IFN‐γ	 and	more	
IL‐10,	 relative	 to	 non‐sensitised	 PBS	 mice,	 after	 in	 vitro	 heat‐killed	 CHE‐
restimulation	 (Fig	 4.1A,	 B).	 Interestingly,	 both	 IFN‐γ	 and	 IL‐10	 levels	 in	 CHE‐
sensitised	 mice	 were	 significantly	 higher	 in	 CD4‐depleted	 (i.e.	 CD4‐	 fraction)	




The	majority	 of	 the	 IFN‐γ	 and	 IL‐10	 producing	 cells	 in	 the	 above	 experiments	
were	T	 cells,	 but	 approximately	30%	was	derived	 from	DCs	and	macrophages.	
Cytokine	 production	 by	 lymphocytes	 alone	 was	 also	 investigated,	 using	 flow	
cytometry	 (Fig	 4.1C).	 In	 CHE‐sensitised	 mice,	 there	 was	 a	 significantly	 lower	
frequency	of	 IFN‐γ	positive	 lymphocytes	 and	but	 a	 similar	percentage	of	 IL‐10	
positive	 lymphocytes,	 relative	 to	 non‐sensitised	 mice.	 This	 complements	 the	
ELISA	 data	 and	 confirms	 that	 CHE‐sensitised	 lymphocytes	 have	 lower	




In	 response	 to	 non‐specific	 stimulation,	 IL‐2	 production	 by	 CD4+	 cells	 of	 CHE‐
sensitised	 mice	 was	 also	 significantly	 lower	 than	 in	 non‐sensitised	 mice	 (Fig	
4.1D).	This	suggested	that,	compared	to	non‐sensitised	mice,	there	was	reduced	
lymphocyte	 activity	 in	 CHE‐sensitised	mice,	 possibly	 related	 to	 soluble	 factors	
induced	by	CHE	sensitisation.	
	
4.3.2	Reduced	 lung	 inflammatory	cells	and	 increased	 lung	cytokines	upon	
BCG	lung	infection	after	CHE	sensitisation		
CHE‐sensitised	and	non‐sensitised	mice	were	given	 live	 i.n.	BCG	and	examined	
one	 or	 three	 weeks	 later.	 The	 frequency	 of	 IFN‐γ	 and	 IL‐10	 producing	
lymphocytes	 in	 the	 lungs	 of	 CHE‐sensitised	 mice	 at	 one	 week	 post‐BCG	 was	
significantly	 higher	 (Fig	 4.2A),	 suggesting	 possible	 cross‐reactive	 T	 cells	
recognising	 common	 antigens	 between	 CHE	 and	 BCG.	 In	 Chapter	 3,	 however,	
post‐BCG	splenic	IFN‐γ	production	by	ELISA	was	similar	between	sensitised	and	
non‐sensitised	mice	 (Fig.	 3.6A).	 Splenic	 IL‐10	 concentrations	were	 lower	 three	
weeks	after	BCG	administration	(Fig	4.2B)	than	before	(Fig	4.1A),	probably	due	
to	 inflammation	 induced	 by	 BCG	 driving	 a	 predominantly	 type	 1	 cytokine	
response.	 In	 spite	 of	 this,	 three‐week	 post‐BCG	 splenic	 IL‐10	 production	 was	
significantly	higher	 in	CHE‐sensitised	mice	than	non‐sensitised	mice	(Fig	4.2B).	
Moreover,	 the	 BAL	 of	 sensitised	 mice	 contained	 fewer	 inflammatory	 cells,	
including	macrophages,	 lymphocytes	and	neutrophils	(Fig	4.2C).	Thus,	systemic	
CHE	priming	resulted	in	a	reduced	inflammatory	response	to	BCG	at	the	site	of	





Mice	were	 either	 given	 i.p.	 heat‐killed	 CHE	 (dark	 bars)	 or	 PBS	 (control,	 white	
bars)	 once	 every	 week	 for	 three	 weeks,	 then	 sacrificed	 a	 week	 after	 the	 last	
exposure.	 The	 splenocytes	 were	 used	 directly	 (“total”),	 or	magnetically	 sorted	
into	 CD4+	 and	 CD4‐	 (CD4‐depleted)	 fractions	 before	 seeding.	 Cells	 were	
stimulated	with	heat‐killed	CHE	or	PBS	(“unstim”)	 for	48	h.	Supernatants	were	
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analysed	 by	 ELISA	 for	 (A)	 IL‐10	 and	 (B)	 IFN‐.	 ND	 =	 not	 detectable.	 (C)	 The	
percentages	of	stimulated	lymphocytes	expressing	IFN‐	or	IL‐10	were	analysed	
by	 flow	 cytometry	 after	 intracellular	 staining	 and	 lymphocyte	 gating.	 (D)	 In	 a	







once	 every	 week	 for	 three	 weeks.	 This	 was	 followed	 one	 week	 later	 by	 i.n.	
administration	 of	 1	 x	 106	 live	 BCG,	 and	 the	mice	were	 sacrificed	 one	 or	 three	
weeks	 post‐BCG	 administration.	 (A)	 One	 week	 post‐BCG,	 lung	 cells	 were	
stimulated	with	PMA	and	ionomycin	for	6	h,	and	percentages	of	T	cells	producing	
IFN‐	 or	 IL‐10	were	analysed	by	ﬂow	cytometry	after	gating	on	CD3+ cells.	 (B)	






Some	Treg	phenotypes	were	 investigated	 in	CHE‐sensitised	mice,	 prior	 to	BCG	
administration,	by	 flow	cytometry.	The	 frequency	of	CD4+CD25+	 cells	was	only	
marginally	 elevated	 in	 CHE‐sensitised	 mice,	 compared	 to	 non‐sensitised	 mice	
(Fig	4.3A).	The	difference	in	proportion	of	CD4+CD25+	cells	expressing	FoxP3,	in	
CHE‐sensitised	 mice,	 was	 unremarkable	 relative	 to	 non‐sensitised	 mice	 (Fig	
4.3B).	However,	as	other	authors	have	suggested	that	there	could	be	differences	
in	functional	CD4+CD25+	activity	despite	no	marked	difference	in	frequency	upon	





Mice	 were	 given	 i.p.	 heat‐killed	 CHE	 or	 PBS	 weekly	 for	 three	 weeks,	 and	
sacrificed	 one	week	 later.	 Their	 splenocytes	were	 analysed	 by	 flow	 cytometry.	
(A)	Percentage	of	CD4+CD25+	cells	in	lymphocyte	gate.	(B)	Percentage	of	FoxP3+	
cells	 within	 the	 CD4+CD25+	 population.	 NS	 =	 not	 significant.	 Statistics	 by	
Student’s	t	test.	
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4.3.4	CD4+CD25+	 cells	 from	 sensitised	mice	 reduce	 IFN‐γ	production	 and	
proliferation	of	co‐cultured	effector	cells	
Therefore,	 the	 functional	 ability	 of	 splenic	 CD4+CD25+	 cells	 of	 CHE‐sensitised	
mice	to	suppress	BCG‐induced,	as	well	as	non‐specific,	lymphocyte	responses	in	
CD4+CD25‐	 effector	 cells	 from	 PBS	 (naïve)	 mice	 was	 next	 investigated.	 This	
effector	cell	fraction	was	co‐cultured	with	either	CD4+CD25+	or	CD4+CD25‐	cells	
from	CHE	or	PBS	mice.	Upon	BCG	antigen	stimulation,	there	was	lower	total	IFN‐
γ	 production	 in	 the	 co‐cultures	 with	 CHE‐derived	 CD4+CD25+	 cells,	 than	 the	
CD4+CD25‐	 fraction	 (Fig	 4.4A).	 This	 implies	 that	 the	 former	 fraction	 caused	
greater	suppression	of	 IFN‐γ	production	by	the	effector	cells	 than	the	 latter,	as	
CHE‐derived	CD4+CD25+	and	CD25‐	cells,	on	their	own,	produced	similar	levels	of	
IFN‐γ	 (C+	vs	C‐:	609.7		 246	vs	507.7		 150.8	pg/	ml).	 It	was	noted,	however,	
that	 both	 the	 CHE‐derived	 fractions	 produced	 higher	 levels	 of	 IFN‐γ	 than	 the	
equivalent	fractions	from	PBS	mice	(P+	vs	C+:	24.2		14.1	vs	609.7		246	pg/	ml,	
p=0.078;	P‐	vs	C‐:	60.6		1.6	vs	507.7		150.8	pg/	ml,	p=0.052),	probably	because	
of	 presence	 of	Mycobacterium‐specific	 effector	 cells	 in	 CHE‐derived	 fractions.	




This	 co‐culture	 experiment	 was	 then	 modified	 to	 investigate	 modulation	 by	
different	 cell	 fractions	 on	 non‐specific	 proliferation	 of	 CD4+CD25‐	 cells	 from	
naïve	 mice,	 in	 response	 to	 anti‐CD3	 and	 anti‐CD28	 (Fig	 4.4B,	 C).	 Significant	
proliferation	was	detected	in	the	co‐culture	with	CD4+CD25‐	cells	from	PBS	mice	
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(i.e.	 P‐	 co‐cultures,	 Fig.	 4.4C),	 showing	 that	 the	 effector	 cells	 from	 naïve	 mice	
responded	 sufficiently	 to	 the	 non‐specific	 stimulation	 for	 suppression	 to	 be	
observed	 in	 other	 co‐cultures.	 The	 CD4+CD25+	 cells	 from	 both	 PBS	 and	 CHE‐
sensitised	 mice	 were,	 as	 expected,	 more	 suppressive	 than	 the	 respective	
CD4+CD25‐	 cells	 from	 the	 same	 sources.	 More	 notably,	 significantly	 lower	
lymphocyte	 proliferative	 activity	was	 observed	 in	 co‐cultures	with	 CD4+CD25+	
cells	 from	 CHE‐sensitised	 mice	 than	 PBS	 mice	 (Fig.	 4.4B,	 C),	 although	 the	
absolute	difference	was	not	large.		
	
After	 BCG	 antigen‐stimulation,	 the	 co‐cultures	 containing	 CHE‐derived	
CD4+CD25+	cells	expressed	the	highest	 levels	of	CD103	in	the	proliferating	cells	
(CFSE‐	 population,	 Fig	 4.4D)	 and	 FoxP3	 in	 the	 lymphocytes	 (Fig	 4.4E).	 This	
supports	the	probability	that	CHE‐derived	CD4+CD25+	cells	were	most	enriched	
for	Treg	cells,	comparing	the	four	co‐cultured	cell	types.	There	was	also	evidence	
(Fig	4.4E)	that	this	cell	 type	led	to	 in	vitro	conversion	of	a	 fraction	of	 the	naïve	
CD4+CD25‐	 cells	 to	 Treg	 cells.	 After	 BCG	 antigen‐stimulated	 culture	 with	
CD4+CD25+	 cells	 from	 CHE‐immunised	 mice,	 the	 CFSE+	 cells,	 which	 were	 the	















percentage	 of	 the	 gated	 population,	 and	 in	 (C)	 the	 mean	 %	 proliferation	 of	 4	 mice	 per	 group	 is	 shown	 ±	 SD	 (this	 is	 a	 graphical	









4.3.5	 Adoptive	 transfer	 of	 CD4+CD25+	 Tregs	 from	 CHE‐sensitised	 mice	
suppresses	BCG	responses		
To	 confirm	 that	 CD4+CD25+	 cells	 from	 CHE‐sensitised	 mice	 could	 mediate	
suppressive	 effects	 in	 vivo	 during	 BCG	 infection,	 adoptive	 transfer	 of	 different	
CD4+	 cell	 fractions	 from	 CHE	 or	 PBS	 mice	 to	 naïve	 mice	 was	 performed,	 just	
before	 administering	 live	BCG	 to	 the	 recipients.	 CD4+CD25+	 cells	 from	CHE‐	 or	
PBS‐sensitised	 mice	 (denoted	 as	 C+	 and	 P+	 cells,	 respectively)	 were	
intravenously	transferred	into	naïve	recipient	mice	(denoted	as	C+	and	P+	mice	
respectively).	 As	 a	 control,	 the	 same	 number	 of	 CD4+CD25‐	 cells	 from	 CHE	 or	
PBS‐sensitised	 mice	 (denoted	 as	 C‐	 and	 P‐	 cells	 respectively)	 were	 separately	
transferred	 to	 naïve	 recipient	 mice	 (denoted	 C‐	 and	 P‐	 mice)	 respectively.	 To	
investigate	 the	modulation	 of	 initial	 responses	 to	 BCG	 in	 recipient	 naïve	mice	
that	was	due	to	the	transferred	cells,	the	mice	were	sacrificed	48	hours	after	live	
i.n.	 BCG	 was	 administered	 to	 all	 recipient	 mice.	 Local	 responses	 in	 the	 lung,	
which	is	the	first	site	for	BCG	infection,	were	examined.	Published	reports	have	





BCG‐specific	 IL‐10	production	 in	the	 lungs	was	higher	 in	C+	mice	than	C‐	mice,	
and	much	elevated	over	P+	and	P‐	mice,	which	showed	minimal	IL‐10	responses	
(Fig	 4.5A).	 Dendritic	 cells	 (DCs)	 formed	 the	 majority	 of	 IL‐10	 expressing	
leucocytes	(53.8	%		4.3	%),	 followed	by	T	 lymphocytes	(39.2	%		16	%)	with	
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only	 a	 minor	 (2	 %	 	 0.7	 %)	 macrophage	 contribution.	 The	 BAL	 fluid	 of	 C+	
recipient	mice	 had	 the	 lowest	 lymphocyte	 counts	 (Fig	 4.5B),	 but	 there	was	 no	
difference	in	other	BAL	leucocytes	(not	shown).	The	frequency	of	IL‐2	producing	
cells	 in	 the	 lungs	 was	 lower	 in	 C+	mice	 compared	 to	 P+	mice	 (Fig	 4.5C).	 The	
differential	 early	 lung	 immune	 responses	 to	BCG	 in	 the	 various	 recipient	mice	
are	likely	to	be	related	to	immune	modulation	by	the	respective	transferred	cells.	
Overall,	the	data	from	the	adoptive	transfer	experiments	suggests	that	the	small	






harvested	 one	 week	 after	 the	 final	 exposure.	 CD4+CD25+	 and	 CD4+CD25‐	 cells	
were	obtained	from	each	mouse	by	magnetic	sorting.	These	cells	(denoted	as	P+,	
P‐,	C+	or	C‐	as	 in	Fig	4.4	 legend)	were	separately	 transferred	 intravenously	 into	
different	naïve	recipient	mice,	which	were	given	one	million	live	BCG	cells	i.n.	on	
the	 same	 day,	 and	 sacrificed	 after	 48	 h.	 (A)	 Lung	 cells	 of	 recipient	 mice	 were	
cultured	in	vitro	with	heat‐killed	BCG	for	48	h	and	supernatants	assayed	for	IL‐10	
production	by	ELISA.	Data	 represent	 three	experiments	with	 similar	 results.	 (B)	
BAL	 fluid	 was	 concentrated	 for	 microscopic	 examination	 of	 lymphocytes	
according	to	Fig	4.2C,	and	results	expressed	as	cell	count	per	ml	of	BAL	fluid.	(C)	







(Belkaid,	 2007).	 Natural	 Tregs	 are	 thymus‐derived	 cells	 that	 serve	 to	 limit	
peripheral	self‐reactive	T	lymphocytes,	and	are	most	commonly	characterised	as	





conversion	 from	 CD25‐	 cells	 in	 peripheral	 lymphoid	 organs	 (Horwitz,	 2008).	
Both	 IL‐10	 and	 TGF‐β	 have	 been	 described	 as	 key	mediators	 of	 Treg‐induced	
effects	 (Sakaguchi,	 2004;	 Horwitz,	 2008).	 Some	 IL‐10	 secreting	 Tregs,	 usually	
known	 as	 Tr1	 cells,	 have	 comparable	 regulatory	 properties	 with	 naturally‐
occurring	 Tregs	 but	 do	 not	 express	 CD25	 or	 FoxP3	 (Vieira,	 2004).	 CD4+CD25+	
cells	in	the	CHE‐sensitised	mice	model	in	this	study	may	potentially	include	both	
natural	 and	 adaptive	 Tregs.	 Although	 this	 study	 failed	 to	 find	 a	 significant	




In	 this	 study,	 mice	 were	 sensitised	 with	 heat‐killed	 CHE.	 Although	 a	 more	
effective	 primary	 response	 could	 potentially	 be	 primed	 with	 live	 Env	
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sensitisation	instead,	natural	human	exposure	to	Env	probably	involves	both	live	
and	dead	Env	 –	 there	 is	 no	 evidence	 that	 only	 live	 Env	 exposure	 can	 result	 in	
human	 sensitisation.	 In	 parallel	 studies	 (described	 in	 Chapter	 5),	 responses	 to	
three	weekly	doses	of	intra‐nasally	administered	106	CFU	live	versus	heat‐killed	
CHE	were	compared,	and	no	differences	in	IFN‐γ	or	IL‐10	production	from	their	
splenocyte	 cultures	 were	 observed.	 Thus,	 both	 live	 and	 dead	 CHE	 may	 have	
similar	 effects	 in	 this	 context.	 As	 immune	 responses	 are	 highly	 dependent	 on	
antigen	loads	(Dhar,	2003;	Lazarevic,	2005;	Russell,	2007b),	it	is	important	to	be	
mindful	of	the	need	for	maximal	consistency	in	reproducing	the	antigen	load	in	
all	 sensitised	mice.	 Therefore,	 in	 this	 study,	 a	 standard,	 batch‐processed,	 non‐
viable	preparation	of	CHE	was	chosen	and	 it	was	 introduced	 through	 the	most	
reproducible	route	(i.e.	intra‐peritoneally).		
	
4.4.3	 Qualitative	 suppressive	 activity	 of	 CD4+CD25+	 Tregs	 without	
quantitative	changes	
CD4+CD25+	 cells	 were	 the	 focus	 of	 this	 study	 because	 of	 the	 many	 published	
reports	on	 such	 cells	 found	 in	Mycobacterium	 infected	hosts.	CD4+CD25+	Tregs	
can	be	expanded	during	the	course	of	human	and	murine	tuberculosis	infection	
and	 suppress	 T	 cell	 mediated	 protective	 responses	 (Guyot‐Revol,	 2006;	
Hougardy,	 2007a;	 Mason,	 2007),	 thus	 facilitating	 pathogen	 persistence.		
CD4+CD25+	 cells	 are	 known	 to	 suppress	 human	 immune	 responses	 to	 BCG	
(Wammes,	2010),	and	impair	Mtb	control	by	CD4+	effector	cells	in	mice	(Kursar,	
2007).	 Inactivation	of	 such	cells	 improves	protection	conferred	by	BCG	against	
Mtb	 challenge	 (Jaron,	 2008).	 Findings	 from	 this	 study,	 that	 the	 CD4+CD25+	
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fraction	 in	 CHE‐sensitised	 mice	 was	 a	 Treg	 population	 with	 functional	








small	 fraction	 of	 activated	 cells.	 Since	 this	 occurred	 upon	 adoptive	 transfer	 to	
wild‐type	recipient	mice	(with	their	existing	full	complement	of	CD4+	T	cells),	it	
suggests	a	potent	effect	of	very	small	numbers	of	CHE‐derived	CD4+CD25+	Tregs	
in	 mediating	 systemic	 suppressive	 effects.	 	 This	 study	 is	 also	 the	 first	 to	
demonstrate	that	functional	activity	of	such	Tregs	from	mice	with	environmental	
mycobacteria	 priming	 is	 qualitatively	 different	 (more	 suppressive)	 than	
CD4+CD25+	cells	from	naïve	mice,	with	respect	to	modulating	a	subsequent	BCG	
response.	 A	 qualitative	 (but	 not	 quantitative)	 difference	 is	 also	 shown	 in	
CD4+CD25+	 cells	 from	 geohelminth‐infected	 people,	which	 substantially	 impair	
immune	 responses	 to	 BCG,	 relative	 to	 the	 same	 cells	 from	 uninfected	 people	
(Wammes,	 2010).	 The	 unremarkable	 frequency	 of	 CD4+CD25+	 cells	 in	 CHE‐
sensitised	mice	(Fig	4.3)	may	be	because	of	concurrent	expansion	of	both	Tregs	
and	 the	 total	 T	 cell	 population	 (including	 effector	 cells)	 in	 Mycobacterium	







and	 macrophages	 (Liu,	 2010)	 to	 produce	 more	 IL‐10,	 this	 explains	 why	 the	
observed	 increase	 in	 systemic	 IL‐10	 production	 in	 CHE‐sensitised	 mice	 is	 not	
entirely	arising	from	IL‐10	secreting	Tregs.	In	fact,	IL‐10	producing	leucocytes	in	
the	 BCG‐challenged	 lungs	 comprised	 of	 54%	 DCs	 and	 40%	 T	 cells,	 consistent	
with	the	fact	that	CD4+CD25+	Tregs	can	skew	pathogen‐stimulated	DCs	towards	
production	 of	 more	 IL‐10,	 whereas	 memory	 CD4+	 T	 cells	 do	 not	 (Veldhoen,	






More	 than	 one	 cell	 type	 in	 CHE‐sensitised	 mice	 could	 have	 Treg	 activity,	 for	
example	 BCG‐immunised	mice	 and	 humans	 have	 CD8+	 Tregs	with	 suppressive	
activity	(Joosten,	2007).	Whether	Tregs	in	CHE‐sensitised	mice	could	operate	via	
other	 cytokines	 or	 non‐cytokine	 mechanisms	 was	 also	 not	 investigated.	 For	
example,	TGF‐β	from	CD4+	Treg	cells,	has	a	role	in	limiting	airway	inflammatory	
responses	after	M.	vaccae	sensitisation	(Zuany‐Amorim,	2002b).	Studies	in	both	
mice	 and	 humans	 have	 suggested	 that	 CD4+CD25‐FoxP3‐	 cells	 could	 undergo	
‘peripheral	 conversion’	 to	 FoxP3+	 Treg	 cells	 under	 different	 stimuli,	 including	
TGF‐β	 (Chen,	2003;	Fantini,	 2004;	Zheng,	2007),	 IFN‐γ	 (Wang,	2006),	 IL‐4	 and	
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IL‐13	 (Skapenko,	 2005),	 or	 prolonged	 exposure	 to	 low‐dose	 antigen	
(Kretschmer,	 2005).	 In	 this	 study,	 some	 CD4+CD25‐	 T	 cells	 from	 naïve	 mice	
acquired	the	FoxP3	marker	in	vitro	when	co‐cultured	with	CD4+CD25+	Treg	cells	
from	CHE‐sensitised	mice	 together	with	BCG	stimulation	 (Fig	4.4E),	 suggesting	
that	 the	 Treg	 cells	 from	 CHE‐sensitised	mice	 may,	 likewise,	 be	 able	 to	 induce	
non‐Treg	 cells	 from	 the	 recipient	 mice	 to	 become	 Tregs	 by	 peripheral	
conversion,	 thereby	 providing	 a	 possible	 additional	mechanism	 for	 the	 in	 vivo	
effects	upon	adoptive	transfer.	The	higher	level	of	expression	of	CD103	observed	
in	CD4+CD25+	cells	from	CHE‐sensitised	mice	than	PBS	mice	after	co‐culture	(Fig	
4.4D)	may	also	be	relevant	 to	 their	 in	vivo	 functions,	as	studies	of	Treg	cells	 in	






equilibrium	 established	 between	 effector	 and	 regulatory	 T	 cells	 has	 been	
elegantly	demonstrated	in	the	chronic	L.	major	murine	infection	model	(Belkaid,	












antigens	 induces	 CD4+CD25hiCD39+	 regulatory	 cells	 associated	 with	 a	 poorer	
Th17	 response	 to	 a	 new	 tuberculosis	 vaccine	 currently	 in	 clinical	 trials	 (de	
Cassan,	2010).	As	Env	exposure	is	inevitable	with	certain	geographical	localities	
and	lifestyles	(Weir,	2006),	 the	findings	 in	this	study	contribute	to	the	growing	
need	 to	 understand	 mechanisms	 by	 which	 Env	 exposure	 affects	 efficacy	 of	
present	and	future	TB	vaccines.			
	 91






reason	 for	 the	 influence	 of	 Env	priming	 on	 subsequent	BCG	 responses	 in	mice	
(Brandt,	 2002;	 Demangel,	 2005).	 In	 mice	 sensitised	 intra‐peritoneally	 with	
different	 heat‐killed	 Env	 species,	 it	 was	 previously	 noted	 (Ho,	 2009)	 that	
sensitisation	with	CHE	primed	higher	cross‐reactive	cytotoxic	responses	against	
autologous	BCG‐infected	macrophages,	 compared	 to	M.	avium	or	M.	 smegmatis.	
Lower	lung	BCG	counts	after	i.n.	BCG	infection	of	CHE‐sensitised	mice,	relative	to	
unexposed	mice	were	also	noted	 (Chapter	3).	 In	 contrast,	Brandt	worked	with	
mice	pre‐sensitised	subcutaneously	with	live	CHE	and	did	not	detect	differences	
from	 naïve	 mice	 in	 their	 splenic	 BCG	 counts	 after	 intravenous	 BCG	 (Brandt,	
2002).	 	The	dose,	route,	viability	and	timing	of	CHE	sensitisation	were	different	









doses	of	 live	CHE,	 and	 to	 live	 and	dead	CHE	were	 compared.	Additionally,	 this	
study	investigated	whether	immune	responses	primed	by	live	CHE	depended	on	
the	 persistence	 of	 live	 organisms	 in	 the	 murine	 host.	 This	 study	 found	 that	
higher	doses	of	 live	CHE	given	 intra‐nasally	resulted	 in	a	stronger	 induction	of	






studies	 compared	 BCG	 vaccination	 responses	 in	 mice	 with	 and	 without	 prior	
intra‐tracheal	 (i.t.)	 low	 dose	 CHE	 sensitisation.	 This	 route	 was	 chosen	 as	 an	
enhancement	 over	 the	 i.n.	 route,	 to	 allow	 more	 accurate	 delivery	 of	 small	
numbers	 of	 CHE	 into	 the	 lungs.	 The	 reduction	 in	 BCG‐specific	 memory	 Th1	
responses,	 associated	 with	 an	 increase	 in	 frequency	 of	 IL‐10	 producing	 CD4+	







purchased	 from	 A*Star	 Biological	 Resource	 Centre	 (BRC)	 and	 used	 under	
protocols	 approved	 by	 the	 NUS	 Institutional	 Animal	 Care	 and	 Use	 Committee	
(IACUC).	 All	 mice	 were	 housed	 in	 filtered	 isolators	 to	 limit	 exposure	 to	
environmental	 organisms.	 To	 determine	 the	 persistence	 of	 CHE	 in	 the	 lungs,	
mice	were	initially	given	103	or	106	CFU	live	CHE	via	the	i.n.	route,	once	a	week	
for	three	weeks,	then	sacrificed	at	weekly	intervals	for	lung	colony	enumeration.	



















After	 incubation,	 cells	were	 removed	 and	 plates	washed	with	 deionised	water	
and	PBS	+	Tween	20.	Secondary	biotinylated	antibodies	were	used	for	detection,	
and	streptavidin‐alkaline	phosphatase	was	added	before	using	the	3‐substrate	3‐
amino‐9‐ethylcarbazole	 substrate	 reagent	 kit	 to	 produce	 a	 color	 change.	 The	







ELISA	 Set	 (BD	 Pharmingen)	 and	 IL‐10	 DuoSet	 (R&D	 Systems)	were	 used,	 and	
cytokine	 levels	 in	the	supernatants	were	measured	based	on	a	sandwich	ELISA	





BSA,	 then	stained	with	relevant	 fluorochrome‐conjugated	antibodies	at	4	 ˚C	 for	
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30	 min	 in	 the	 dark	 and	 fixed	 with	 4	 %	 paraformaldehyde	 before	 use.	 For	
intracellular	 staining,	 cells	 were	 permeabilised	 with	 PBS	 containing	 0.1	 %	
saponin	(Sigma)	or	with	the	intracellular	(IC)	staining	or	permeabilisation	buffer	
set	 (eBioscience)	 after	 fixing,	 then	 blocked	with	 PBS	 containing	 0.5%	BSA	 and	
0.1	%	saponin	 for	30	min	at	4	 ˚C,	before	staining	with	relevant	antibodies.	The	
following	anti‐mouse	antibodies	were	used:	CD3	(145‐2C11,	BD	Biosciences),	Gr‐
1	 (RB6‐8C5,	 BioLegend),	 CD11c	 (N418,	 BioLegend),	 F4/80	 (BM‐8,	 BioLegend),	
CD4	 (RM4‐5,	 BD	 Biosciences),	 CD8	 (53‐6.7,	 BioLegend),	 CD25	 (PC61,	 BD	
Biosciences),	 CD62L	 (MEL‐14,	BioLegend),	CD44	 (IM7,	BD	Biosciences),	 CD127	
(SB/199,	 BioLegend),	 IFN‐	 (XMG1.2,	 BD	 Biosciences),	 GITR	 (YGITR	 765,	





of	 Flow‐Count	 Fluorosphere®	 (Beckman	Coulter)	which	provided	 the	 reference	










80	 ˚C	 until	 use.	 To	 determine	 the	 proportion	 of	 splenocytes	 actively	 secreting	
IFN‐γ	 after	 TB10.4	 (5	 g/	 ml)	 antigen	 or	 PBS	 stimulation,	 the	 mouse	 IFN‐γ	
secretion	assay	–	cell	enrichment	and	detection	kit	(Miltenyi	Biotec)	was	utilised	
according	 to	 manufacturer’s	 instructions.	 Briefly,	 splenocytes	 were	 seeded	 in	
tissue	culture	plates	and	harvested	after	24	h	of	antigen	stimulation.	Cells	were	
then	 labelled	 with	 an	 IFN‐γ	 specific	 ‘catch	 reagent’	 at	 4	 °C	 for	 15	 min,	 then	
topped	up	with	warm	RPMI	and	incubated	at	37	°C	with	constant	mixing	for	4	h.	
Cells	were	then	washed	with	cold	PBS	+	0.5	%	BSA	and	stained	with	detection	
antibody	 (conjugated	 to	 PE)	 together	 with	 antibodies	 specific	 for	 other	 cell	











5.3.1	 Differential	 persistence	 of	 CHE	 in	murine	 lungs	 at	 different	 intra‐
nasal	doses		
Lung	 CHE	 sensitisation	 with	 103	 CFU	 CHE	 thrice	 one	 week	 apart	 sufficed	 to	
suppress	 in	vivo	BCG	responses	–	 this	 is	described	more	 fully	 in	Fig	5.5A.	With	
this	 preliminary	 knowledge	 on	 minimal	 dosage	 for	 a	 suppressive	 effect,	 the	
differences	 in	 immune	responses	primed	by	a	 low	(103	CFU)	or	high	(106	CFU)	
dose	of	live	CHE	given	thrice	once	a	week	via	the	i.n.	route	were	investigated,	to	




















given	high	dose	 than	 low	dose	CHE,	consistent	with	 the	higher	antigen	 load.	 In	
low	dose	CHE‐sensitised	mice,	IFN‐	production	was	higher	at	week	6	than	week	
2,	 although	 CHE	 was	 cleared	 by	 week	 2.	 This	 suggests	 a	 build‐up	 of	 memory	
responses	 to	 the	 common	 antigens	 even	 without	 presence	 of	 viable	 CHE.	 The	





as	 has	 been	 noted	 with	 M.	 vaccae	 sensitisation	 (Hernandez‐Pando,	 1997).	
However,	IL‐10	was	unlikely	to	be	the	mediator	of	these	suppressive	effects,	as	

















5.3.3	High	 dose	 CHE	 induced	 stronger	 Treg	 responses	 and	weaker	 IFN‐	
responses	
To	 verify	 if	 high	 dose	 CHE	 induced	 stronger	 regulatory	 T	 cell	 responses,	 the	
frequency	of	 lung	and	splenic	Tregs	was	studied	by	flow	cytometry.	The	higher	
CHE	 dose	 led	 to	 significantly	 stronger	 induction	 of	 CD4+CD25+	 cells	 and	 CD4+	
cells	of	CD25+GITR+	phenotype,	respectively	in	the	lungs	at	the	early	(Fig.	5.2A)	
and	 spleens	 at	 the	 late	 time‐point	 (Fig.	 5.2B)	 compared	 to	 lower	 dose	 CHE	
sensitisation.	 Thus,	 the	 dose	 of	 CHE	 affects	 the	 extent	 of	 Treg	 induction,	 with	
local	 (lung)	 effects	 being	 observable	 earlier	 than	 systemic	 (splenic)	 effects.	
However,	the	absolute	magnitude	of	difference	was	small.	Treg	responses	to	low	
dose	 CHE	 were	 significantly	 stronger	 at	 week	 6	 than	 week	 2,	 despite	 the	
clearance	of	CHE	from	the	lungs	(Fig.	5.2A).	This	could	be	due	to	persistence	of	
inflammatory	 processes	 triggered	 by	 CHE	 exposures	 maintaining	 Treg	






CD11c+	 DCs	 (Fig.	 5.3).	 Thus,	 at	 week	 6	 after	 high	 dose	 i.n.	 CHE,	 there	 was	
increased	 local	 lung	 lymphocyte	 activity	 relative	 to	 week	 2,	 although	 the	







Mice	were	 given	 i.t.	 103	 or	 106	 CFU	 CHE	 or	 PBS	 as	 described	 in	 Fig.	 5.1A,	 and	
sacrificed	two	or	six	weeks	after	 initial	administration	of	CHE.	The	frequency	of	
(A)	CD4+CD25+	 cells	 gated	on	CD3+	 cells	 in	 the	 lungs	and	 (B)	CD25+GITR+	 cells,	






Inflammatory	 cells,	 namely	 T	 cells	 (CD3),	 DCs	 (CD11c),	 neutrophils	 (Gr‐1)	 and	
macrophages	(F4/80),	from	lung	tissue	of	mice	sensitised	with	106	CFU	live	CHE	
at	 two	 or	 six	 weeks	 after	 initial	 CHE	 sensitisation	 were	 analysed	 by	 flow	






This	study	next	 investigated	 the	responses	 to	 live	versus	dead	106	CFU	CHE	 to	
directly	 compare	 their	 effects	 on	 Treg	 induction	 and	 IFN‐	 production.	 The	
frequency	of	CD25+GITR+	 cells	out	of	 all	 splenic	CD4+	 lymphocytes	was	 similar	
between	mice	given	 live	and	dead	CHE	(Fig.	5.4A)	at	both	weeks	2	and	6.	This	
Treg	 frequency	persisted	even	after	CHE	was	cleared	at	week	6.	This	 indicated	
that	 the	 viability	 of	 CHE	 used	 for	 sensitisation	 did	 not	 significantly	 affect	
induction	 of	 CD4+	 Tregs	 with	 the	 CD25+GITR+	 phenotype.	 Although	 the	
difference	 was	 not	 statistically	 significant,	 there	 was	 a	 3‐fold	 higher	 IFN‐	
response	in	mice	given	dead	CHE	than	those	given	live	CHE	at	week	6		(Fig.	5.4B).	
This	difference	was	not	observed	at	week	2.	 IL‐10	 levels	were	 the	same	 in	 live	
and	dead	CHE	sensitised	mice	at	both	time‐points	(Fig.	5.4B).			
	





are	 suppressed	 by	 prior	 CHE	 sensitisation.	 The	 CD62LloCD127hi	 subset	 of	
memory	 cells	 is	 expanded	 in	 the	 organs	 of	 Mtb‐infected	 mice	 and	 they	 are	
believed	 to	 be	 important	 for	 protection	 against	 TB	 (Henao‐Tamayo,	 2010).	
TB10.4	 is	 highly	 immunogenic	 in	 BCG‐vaccinated	 individuals	 and	 TB	 patients,	
inducing	 strong	 IFN‐	 responses	 in	 such	persons	 (Skjot,	2000;	Skjot,	2002).	An	
increase	 in	 TB10.4‐specific	 IFN‐	 responses	 in	 Treg‐neutralised	 mice	 is	
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associated	 with	 reduced	 Mtb	 load	 upon	 challenge	 (Jaron,	 2008).	 High	
frequencies	of	TB10.4	specific	CD4+	T	cells	correlate	with	protection	against	Mtb	




significant	 reduction	 in	 frequency	 of	 BCG‐specific	 IFN‐	 producing	 cells,	 upon	
stimulation	 with	 heat‐killed	 BCG	 (Fig.	 5.5A)	 and	 TB10.4	 epitope	 (Fig.	 5.5B),	
compared	 to	 non‐sensitised	mice.	Memory	 responses	 to	 BCG	 vaccination	were	
reduced	 in	CHE	 sensitised	mice,	 evidenced	by	 a	 smaller	proportion	 of	 TB10.4‐
specific	 IFN‐+	memory	cells	of	 the	CD127+CD62Llo	phenotypes	(Fig.	5.6).	Thus,	
CHE	 sensitisation	 suppressed	 BCG‐specific	 memory	 IFN‐	 responses.	 	 As	 the	
TB10.4	 epitope	 is	 not	 a	 CHE	 antigen,	 this	 suppression	 is	 unlikely	 to	 be	 due	 to	
cross‐reactive	 Tregs.	 	 However,	 Mycobacterium‐specific	 nTregs	 can	 restrict	
expansion	of	 effector	T	 cells	whose	epitope	 specificity	differs	 from	 the	epitope	
recognised	by	the	Tregs	(Shafiani,	2010).	It	is	also	possible	that	the	suppression	
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(A)	 The	 proportion	 of	 CD25+GITR+	 cells,	 gated	 on	 CD4+	 cells,	 in	 the	 spleens	 of	











Splenocytes	 from	 vaccinated	 mice	 (BCG),	 CHE	 sensitised	 and	 vaccinated		
(CHE+BCG)	or	control	(PBS)	mice	were	stimulated	with	(A)	heat‐killed	BCG	or	(B)	
a	TB10.4	peptide	(a	BCG	epitope	not	found	in	CHE;	“stim”)	or	PBS	(“unstim”)	for	
24h	 and	 frequency	 of	 IFN‐+	 cells	 determined	 by	 (A)	 ELISpot	 or	 (B)	 cytokine	
capture	followed	by	 flow	cytometry.	Analysis	was	gated	on	 lymphocytes	(B)	and	
the	proportion	of	IFN‐	producing	memory	cells	was	determined.	Data	shown	are	








Splenocytes	 from	 vaccinated	 mice	 (BCG),	 CHE	 sensitised	 and	 vaccinated		
(CHE+BCG)	or	control	 (PBS)	mice	were	stimulated	with	TB10.4	peptide	(“stim”)	
or	PBS	 (“unstim”)	 for	24h	and	 the	 frequency	of	 IFN‐+	 cells	was	determined	by	
cytokine	 capture	 and	 flow	 cytometry.	 Analysis	was	 gated	 on	 CD4+	 lymphocytes	
and	 the	 proportion	 of	 (A)	 CD44hiCD62Llo	 and	 (B)	 CD127+CD62Llo	memory	 cell	
subsets	 producing	 IFN‐.	 gated	 on	 CD4+	 cells,	 was	 determined.	 Data	 shown	 are	




5.3.7	 Systemic	 increase	 in	 IL‐10	 producing	 cells	 with	 CHE	 sensitisation	
before	BCG	vaccination	
After	BCG	vaccination,	significantly	higher	frequencies	of	splenic	IL‐10	producing	
cells	 (by	 ELISpot)	 and	 CD4+	 IL‐10‐secreting	 lymphocytes	 (by	 flow	 cytometry)	
were	 observed	 in	 CHE‐sensitised	 mice	 (Fig.	 5.7),	 compared	 to	 non‐sensitised	
mice,	 in	 response	 to	heat‐killed	BCG	stimulation.	This	 suggests	 the	presence	of	
adaptive	Tregs	 induced	upon	prior	CHE	exposure	 followed	by	BCG	vaccination.	
This	 increase	 in	 systemic	 IL‐10	 may	 be	 one	 possible	 explanation	 for	 the	
suppression	of	 splenic	 IFN‐	 responses	 to	BCG	antigens	 in	CHE‐sensitised	mice	
post‐vaccination.	 Other	 laboratory	 colleagues	 subsequently	 showed	 that	





Fig.	 5.7:	 Higher	 frequency	 of	 IL‐10	 producing	 adaptive	 Tregs	 in	 BCG‐
vaccinated	mice	with	prior	CHE	exposure	
Splenocytes	 from	 vaccinated	 mice	 (BCG)	 or	 vaccinated	 mice	 with	 prior	 CHE	
sensitisation	(CHE+BCG)	were	stimulated	with	heat‐killed	BCG	for	72	h.	(A)	IL‐10+	
cells	were	then	detected	via	ELISpot	or	(B)	stained	by	cytokine	capture	for	IL‐10,	




5.3.8	 Differential	 phenotype	 of	 IL‐10	 producing	 cells	 in	 BCG	 vaccinated	
mice	with	and	without	CHE	sensitisation	
The	surface	phenotype	of	IL‐10	producing	cells	was	investigated.	About	80%	of	
IL‐10	 producing	 CD4+	 cells	 in	BCG‐vaccinated	mice	were	 of	 the	 conventionally	
described	 Tr1	 cell	 phenotype	 (i.e.	 CD25‐FoxP3‐).	 However,	 in	 mice	 with	 CHE	
sensitisation	 before	 BCG	 vaccination,	 CD4+IL‐10+	 cells	 were	 predominantly	
CD25‐FoxP3+	(~70%),	suggesting	that	CHE	sensitisation	induced	a	different	type	
of	 IL‐10	 secreting	 adaptive	 Tregs,	 relative	 to	 BCG	 vaccination	 alone.	 These	









a	 significantly	 higher	 frequency	 of	 FoxP3+	 lymphocytes	 and	 cells	 with	 the	
CD25+FoxP3+	phenotype	within	the	CD4+	lymphocyte	population	(Fig.	5.8).	This	
is	a	phenotype	commonly	associated	with	nTregs.	It	suggests	that	with	repeated	
CHE	 exposure	 before	 BCG	 vaccination,	 a	 higher	 frequency	 of	 nTregs	 can	 be	











(A)	 FoxP3+	 and	 (B)	 CD25+FoxP3+	 was	 determined,	 gated	 on	 CD4+	 lymphocytes.	







in	 the	host,	 it	was	 important	 to	 investigate	how	different	exposure	parameters	
affect	 the	 initial	 and	 subsequent	 host	 responses	 to	 Env.	 The	 present	 findings	
suggest	that	higher	bacterial	loads	lead	to	more	Treg	induction,	associated	with	






M.	 tuberculosis	 at	 low	doses	 induces	 antigen‐specific	 Th1	 cellular	 responses	 in	
the	 lungs	more	 slowly	 than	 high	 doses	 (Yahagi,	 2010).	 Likewise,	 with	 inhaled	




CD25+GITR+	 type	 of	 CD4+	 cells,	which	 are	 known	 to	 have	 regulatory	 functions	
(McHugh,	2002),	was	observed	within	 a	week	of	 first	 exposure	 in	 the	 lungs	of	
mice	given	high	dose	CHE,	even	though	at	that	same	time	point	(week	2),	there	
were	 strong	 systemic	 IFN‐γ	 responses.	 Given	 the	 temporal	 link	 of	 higher	
frequency	 of	 splenic	 Tregs	 at	week	 6	 (relative	 to	 low	 dose	 group)	with	 lower	
systemic	 IFN‐	 responses	 in	 the	high	dose	group,	 it	 is	 tempting	 to	suspect	 that	
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Mycobacterium‐specific	 nTregs	 may	 have	 contributed	 to	 this.	 GITR	 is	 highly	
expressed	 on	 Tregs	 (Belkaid,	 2007).	 GITR	 signalling	 triggers	 the	 expansion	 of	
functional	Tregs	(Ji,	2004;	Nishioka,	2008),	and	GITR	expression	on	Treg	cells	is	
higher	 in	 TB	 patients	 who	 have	 reduced	 BCG‐specific	 IFN‐	 response	 in	 CD4+	











activating	 T	 cell	 subsets	 specific	 for	 proteins	 secreted	 by	 live	 mycobacteria.	
(Daugelat,	 1995).	 In	 contrast,	 other	 studies	 suggest	 that	 live	 and	 dead	 BCG	
induce	similar	local	responses	(Chambers,	1997).	Findings	in	Chapter	3	showed	
that	 heat‐killed	 CHE	 sensitisation	 induced	 cytotoxicity	 against	 BCG‐infected	
macrophages,	 and	 reduced	BCG	 replication,	 therefore	 immune	priming	 against	
BCG	 clearly	 occurs	 even	 with	 dead	 CHE.	 A	 study	 on	 oral	 administration	 of	
different	 live	 strains	 of	M.	 avium	 (Young,	 2007)	 suggests	 that	 the	 strain	 that	
persists	 longer	 in	 the	 host	 is	 less	 likely	 to	 trigger	 pro‐inflammatory	 cytokine	
secretion,	and	also	 tends	 to	 induce	greater	suppression	of	 IFN‐	 responses	and	
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antibody	 responses	 biased	 towards	 a	 Th2	 phenotype.	 This	 suggests	 that	 Env	
species	with	 longer	persistence	may	 limit	 the	BCG	response	more	significantly.	
However,	elimination	of	 live	M.	avium	with	antibiotics	given	 to	 the	host	before	
BCG	 vaccination	 still	 led	 to	 suppression	 of	 BCG	 counts	 and	 IFN‐	 responses	
(Brandt,	2002),	 so	 the	nature	of	memory	 responses	 imprinted	 in	 the	host	may	
not	 be	 entirely	 determined	 by	 the	 persistence	 of	 the	 species	 during	 BCG	
vaccination.	Indeed,	heat‐killing	or	antibiotic	mediated	lysis	of	mycobacteria	may	
release	 intracellular	antigens,	 contributing	 to	greater	 immunogenicity	 than	 live	
mycobacteria,	which	usually	 have	means	of	 evading	host	 immunity	 if	 they	 live	
intracellularly.	 In	 this	 present	 study,	 splenic	 Treg	 or	 BCG‐specific	 IFN‐	
responses	primed	by	i.n.	CHE	exposure	were	not	substantially	different	with	live	
or	 dead	 (heat‐killed)	 CHE	 sensitisation	 (Fig.	 5.4).	 Moreover,	 most	 responses	
were	undiminished	or	even	elevated	when	tested	beyond	the	point	of	in	vivo	live	
persistence	 of	 CHE	 (Figs	 5.2	 and	 5.3).	 This	 implies	 that	 the	 memory	 and	
regulatory	 responses	 induced	 by	 CHE	 are	 similar	 whether	 the	 host	 was	
sensitised	by	live	or	dead	CHE.		
	
5.4.3	 Implications	 of	 dose‐dependent	 immune	 induction	 with	 CHE	
exposure	
The	multiple	 Env	 species	 often	 identified	 in	 urban	water	 sources	 (Vaerewijck,	






comparing	 studies	 investigating	 the	 impact	 of	 Env	 on	 BCG	 vaccine	 efficacy.	 As	
higher	 doses	 of	 CHE	 led	 to	 higher	 levels	 of	 Treg	 responses	 and	 weaker	 BCG‐
specific	IFN‐γ	responses	pre‐vaccination,	it	 is	tempting	to	speculate	that	people	
who	are	highly	exposed	to	Env	may	be	primed	to	have	poorer	responses	to	BCG.	
The	 converse	 point	 is	 also	 interesting	 –	 that	 low	 dose	 repeated	 inhaled	 CHE	
priming	 could	 lead	 to	 enhanced	 memory	 to	 BCG	 antigens	 over	 time	 through	
cross‐reactivity,	 as	 this	 method	 of	 sensitisation	 has	 less	 immediate	 impact	 on	
systemic	 Treg	 induction.	 Indeed,	 this	 led	 us	 to	 directly	 examine	 whether	 low	





was	 observed	 from	 inhaled	 CHE	 exposure	 alone.	 In	 fact,	 induction	 of	 both	
systemic	nTregs	 and	adaptive	 (infection‐induced)	Tregs	was	noted.	 IL‐10	 is	 an	
anti‐inflammatory	cytokine	that	 is	particularly	 important	 in	suppressive	effects	
induced	 by	 adaptive	 Tr1	 cells	 (Roncarolo,	 2006).	 Env	 such	 as	 M.	 avium	 can	
induce	 the	 production	 of	 IL‐10	 (Bermudez	 and	 Champsi,	 1993)	 and	
neutralisation	 of	 IL‐10	 improves	 resistance	 to	 systemic	 murine	 M.	 avium	
infection,	 associated	with	 enhanced	macrophage	activity	 (Denis	 and	Ghadirian,	
1993).	Excessive	 IL‐10	production	 in	 IL‐10	 transgenic	mice	 increases	M.	avium	
infection	and	decreases	macrophage	effector	function	(Feng,	2002).		Anergic	TB	
patients	who	do	not	 respond	 to	 intra‐dermal	purified	protein	derivative	 (PPD)	
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have	 high	 peripheral	 blood	 levels	 of	 IL‐10,	 which	 is	 additionally	 linked	 to	
suppression	 of	 IFN‐	 production	 and	 T	 cell	 proliferation	 (Boussiotis,	 2000).	
These	studies	clearly	show	that	IL‐10	impairs	Mycobacterium	pro‐inflammatory	
responses.	CHE‐sensitised	mice	had	more	IL‐10	producing	cells	post	vaccination	
(Fig.	 5.7),	 which	 are	 more	 likely	 to	 be	 CHE‐induced	 adaptive	 Tregs,	 although	
their	 phenotype	 was	 not	 consistent	with	 Tr1	 cells.	 As	 discussed	 earlier,	 these	
cells	may	potentially	be	due	to	peripheral	conversion	of	CD4+CD25‐	cells	 in	 the	
presence	of	bacteria	(Littman	and	Rudensky,	2010).	The	IL‐10	in	CHE‐sensitised	
mice	 post‐vaccination	 appears	 to	 be	 the	 main	 cause	 of	 suppressed	
Mycobacterium‐specific	 IFN‐γ.	 This	 is	 supported	 by	 the	 temporal	 association	
with	the	latter,	and	by	restoration	of	systemic	BCG‐specific	IFN‐	levels	with	IL‐








It	 is	 notable	 that	 with	 BCG	 vaccination	 alone,	 restimulation	 of	 splenic	
lymphocytes	 in	vitro	with	BCG	antigens	gave	very	minimal	expansion	of	nTregs	
(CD4+CD25+FoxP3+),	 whereas	 repeated	 inhaled	 CHE	 exposure	 before	 BCG	
vaccination	 increased	 systemic	 frequency	 of	 such	 cells	 (Fig	 5.8).	 This	
phenomenon	 is	 consistent	 with	 Shafiani’s	 observations	 in	 the	 context	 of	 Mtb	
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10‐producing	 adaptive	 Tregs,	 with	 associated	 suppression	 of	 IFN‐	 memory	
responses	 specific	 for	 BCG	 antigens.	 These	 factors	 are	 known	 to	 be	 correlated	
with	 poor	 protection	 against	 TB,	 and	 are	 therefore	 likely	 to	 result	 in	 negative	
effects	of	CHE	priming	on	BCG	vaccine‐induced	protection.	Importantly,	marked	
differences	were	observed	in	nature	of	systemic	Treg	responses	before	and	after	
BCG	 vaccination	 in	 CHE‐primed	mice.	 These	 differences	may	 explain	why	 in	 a	
study	 of	 human	 infants	 with	 delayed	 BCG	 vaccination,	 the	 frequency	 of	
peripheral	blood	nTregs	before	vaccination	did	not	 correlate	with	 the	 levels	of	
Mycobacterium‐specific	 IFN‐	 after	 vaccination	 (Burl,	 2010),	 although	 it	 was	
noted	 that	 vaccination	 delay	 (allowing	 time	 for	 natural	 Env	 exposure)	 led	 to	
poorer	IFN‐	responses	compared	to	vaccination	at	birth.	In	the	above	study,	it	is	
possible	that	the	 induction	of	adaptive	IL‐10	producing	Tregs	and	expansion	of	
nTregs	 post‐BCG	 vaccination	 in	 Env‐primed	 subjects,	 rather	 than	 nTreg	
frequency	before	 vaccination,	may	be	more	 correlated	with	 the	post‐BCG	 IFN‐	
suppression.	 The	 implication	 is	 that	 post‐BCG	 vaccination	 Treg	 assays	may	 be	
more	pertinent	for	assessing	the	real	effect	of	Env	priming.	The	findings	 in	this	
study	 lend	 support	 to	 the	 theoretical	 proposition	 (Shafiani,	 2010)	 that	
neutralisation	 of	 Tregs	 before	 BCG	 vaccination	may	 lead	 to	 better	 vaccination	
outcomes.		
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CHAPTER	 6	 –	 Mycobacterium	 chelonae	 exposure	 after	 BCG	 vaccination	




A	 large	 body	 of	 evidence	 suggests	 that	 exposure	 to	 non‐tuberculous	 Env	
interferes	with	BCG‐attributable	protection,	but	most	studies	were	conducted	in	
the	 context	 of	 pre‐BCG	 Env	 exposure	 (Collins,	 1971;	 Orme	 and	 Collins,	 1984;	
Black,	2001a;	Brandt,	2002;	Demangel,	2005).		Given	that	the	WHO	recommends	
that	 BCG	 vaccination	 be	 administered	 at	 birth	 (WHO,	 2005),	 there	 should	
theoretically	 be	 little	 Env	 exposure	 before	 vaccination,	 unless	 vaccination	 is	
delayed.	 However,	 post‐vaccination	 exposure	 to	 M.	 avium	 also	 compromises	
subsequent	BCG‐induced	protection	in	mice	(Flaherty,	2006)	and	human	studies	





This	 study	 focused	 on	 discovering	 how	 post‐BCG	 vaccination	 exposure	 to	 Env	
alters	BCG	responses	 in	mice.	 	Effects	of	the	rapid	grower	–	CHE,	were	studied,	
following	earlier	findings	(Chapters	4	and	5)	that	pre‐BCG	exposure	to	this	Env	
species	 negatively	 affected	 subsequent	 BCG	 recall	 responses.	 Oral	 and	 inhaled	
routes	of	CHE	exposure	were	studied	because	 these	are	 the	more	 likely	 routes	
for	 natural	 human	 exposure	 to	 Env	 (Primm,	 2004).	 After	 BCG	 vaccination	 of	
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weanling	 mice,	 the	 impact	 of	 giving	 CHE	 early	 post‐vaccination	 during	 initial	
development	 of	 memory	 responses	 to	 BCG,	 was	 compared	 against	 late	 CHE	









Specific	 pathogen‐free	BALB/c	mice	 (AnN	 from	Taconic)	were	 bred	within	 the	
animal	 facility	 approved	 by	 Association	 for	 Assessment	 and	 Accreditation	 of	
Laboratory	 Animal	 Care	 International,	 under	 protocols	 approved	 by	
Massachusetts	Institute	of	Technology	(MIT)	Committee	on	Animal	Care.	Breeder	
mice	 were	 housed	 in	 individual	 isolator	 cages	 with	 filter	 tops.	 Newly	 weaned	
mice	were	then	sexed	and	removed	to	new	cages	with	sterile	synthetic	bedding,	




Bacteria	 strains	 and	 preparation	 were	 as	 previously	 described	 in	 Chapter	 3	
(Section	 3.2.2	 and	 3.2.3).	 Newly	 weaned	 mice	 were	 vaccinated	 with	 live	 BCG	
subcutaneously	with	106	CFU	live	BCG,	and	were	subsequently	immunised	with	
500	CFU	live	CHE	via	the	intra‐tracheal	(i.t.)	route	at	either	two	or	twelve	weeks	
post‐vaccination,	 once	 a	 week	 for	 three	 weeks,	 or	 given	 continuous	 live	 CHE	
exposure	 in	 drinking	water	 at	 50	 CFU/	ml.	Mice	were	 subsequently	 sacrificed	
two	 weeks	 after	 the	 last	 CHE	 exposure.	 In	 some	 experiments,	 mice	 were	
challenged	 with	 106	 live	 BCG	 via	 the	 i.t.	 route,	 two	 weeks	 after	 the	 last	 CHE	








T	 cell	 enriched	 splenocytes	 were	 seeded	 at	 0.5	 x	 106	 cells/	 well	 in	 96‐well	
ELISpot	plates	and	stimulated	with	heat‐killed	BCG	(10	bacteria:	1	cell)	or	PBS	




T	 cell	 enriched	 splenocytes	were	 seeded	 at	 0.25	 x	 106	 cells/	well	 in	 96‐well	 U‐
bottom	 tissue	 culture	plates	and	stimulated	with	heat‐killed	BCG	 (10	bacteria:	1	
cell)	or	PBS	 for	48	h	 to	detect	 cytokine	 secretion.	 Supernatants	were	harvested	
and	kept	at	 ‐20	°C	until	use.	Analysis	of	cytokines	and	chemokines	 in	 the	 lungs	
was	 conducted	 after	 protein	 isolation.	 Protein	 from	 lung	 samples	 was	 isolated	
directly	 from	 frozen	 tissue	 by	 homogenisation	 in	 cell	 lysis	 buffer	 containing	
phosphatase	and	protease	 inhibitors	according	 to	manufacturer's	protocol	 (Bio‐
Rad).	 Cytokine	 and	 chemokine	 levels	 were	 measured	 in	 supernatants	 and	 lung	
lysates	using	Bio‐Plex	Pro	Mouse	cytokine/	chemokine	multiplex	assay	according	
to	 manufacturer's	 instructions	 (Bio‐Rad).	 Briefly,	 relevant	 wells	 on	 plates	 were	





incubation	 periods	 respectively,	 with	 washing	 in	 between.	 A	 final	 wash	 step	 is	
performed	before	the	beads	were	resuspended	in	diluent	buffer.	Plates	were	then	
processed	on	the	Luminex	200	suspension	array	system	using	the	low	RP1	target	
setting	 (High	 PMT)	 for	maximum	 sensitivity.	Data	was	 analysed	 on	 the	Bio‐Plex	
ManagerTM	5.0	software	and	cytokine	concentrations	calculated	using	a	standard	
curve	 generated	 by	 either	 4PL	 or	 5PL	 curve	 fitting.	 Total	 protein	 in	 each	 lung	
sample	was	measured	using	the	micro	BCA	assay	kit	(Thermo	Fischer	Scientific	





BSA,	 then	stained	with	relevant	 fluorochrome‐conjugated	antibodies	at	4	 ˚C	 for	
30	 min	 and	 fixed	 with	 4	 %	 paraformaldehyde	 before	 use.	 For	 intracellular	
staining,	 cells	 were	 first	 surface	 stained	 as	 described	 above,	 then	 fixed	 and	
permeabilised	 using	 the	 FoxP3	 staining	 buffer	 set	 (eBioscience)	 according	 to	
manufacturer’s	 instructions.	 Cells	 were	 next	 blocked	with	 purified	 anti‐mouse	
CD16/CD32	antibodies	(BD	Pharmingen)	 in	permeabilisation	buffer	 for	30	min	
at	 4	 ˚C,	 before	 staining	 with	 relevant	 intracellular	 antibodies,	 with	 relevant	
isotype	 controls.	 In	 some	 experiments,	 splenocytes	were	 seeded	 at	 0.25	 x	 106	
cells/	well	 in	 96‐well	U‐bottom	 tissue	 culture	 plates	 and	 stimulated	with	PMA	
(12.5ng/	 ml)	 and	 ionomycin	 (500	 ng/	 ml)	 for	 18‐19	 h	 before	 harvesting	 for	
surface	staining	and	flow	cytometry.	The	following	anti‐mouse	antibodies	were	
used:	 CD3e	 (145‐2C11,	 eBioscience),	 Gr1	 (RB6‐8C5,	 BD	 Pharmingen),	 CD11b	
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(M1/70,	 eBioscience),	 F4/80	 (BM8,	 eBioscience),	 CD4	 (GK1.5,	 eBioscience),	
CD8a	 (53‐6.7,	 eBioscience),	 CD25	 (PC61.5,	 eBioscience),	 CD62L	 (MEL‐14,	
eBioscience),	 CD44	 (IM7,	 eBioscience),	 GITR	 (DTA‐1,	 eBioscience),	 and	 FoxP3	
(FJK‐16s,	eBioscience),	 along	with	 relevant	 isotype	controls	 in	negative	control	




was	 obtained	 by	 determining	 the	 concentration	 of	 cells	 within	 the	 flow	
cytometry	sample	via	the	C6	flow	cytometer	(Accuri	Cytometers).	The	absolute	
number	of	lung	cells	was	then	calculated	by	multiplying	that	by	the	total	volume	









To	 simulate	 BCG	 vaccination	 at	 birth,	 newly	 weaned	 Balb/c	 mice	 were	 BCG‐








enumerating	 frequencies	 of	 splenic	 IFN‐	 secreting	 cells	 after	 heat‐killed	 BCG	
stimulation.	After	BCG	vaccination,	early	CHE	exposure	led	to	an	increase	in	BCG‐
specific	IFN‐	secreting	cells	upon	lung,	but	not	oral	exposure	(Fig.	6.1B).	At	late	
exposure,	 neither	 route	 of	 CHE	 exposure	 altered	 IFN‐	 responses	 to	 BCG.	 It	 is	
possible	that	BCG	responses	that	could	be	boosted	by	CHE	were	relatively	short‐
lived,	since	responses	were	no	longer	enhanced	when	BCG	vaccination	and	CHE	
exposure	 were	 further	 apart	 in	 time.	 Alternatively,	 CHE	 may	 have	 induced	











(A)	 Pre‐challenge	 time	 course	 for	 BCG	 vaccination,	 exposure	 to	 CHE	
intratracheally	 (CHE‐T)	 or	 orally	 through	 the	 water	 supply	 (CHE‐O),	 and	
necropsy.	(B,	C)	The	frequency	of	IFN‐γ	producing	splenocytes	was	determined	by	




per	 million	 cells	 (of	 6‐16	 mice	 from	 multiple	 necropsies)	 ±	 SEM.	 ND	 =	 not	





Subsequent	 studies	 focused	 on	 lung	 exposure	 to	 CHE,	 since	 this	 route	 had	 a	
greater	influence	on	BCG‐specific	IFN‐	responses	than	oral	CHE	exposure.	After	
splenocyte	 stimulation	 with	 heat‐killed	 BCG	 for	 48	 h,	 no	 differences	 in	 IFN‐	
production	by	ELISA	were	observed	 in	 vaccinated	mice	with	 and	without	 lung	
CHE	 exposure,	 at	 either	 the	 early	 or	 late	 time	 points.	 Nonetheless,	 IFN‐	
production	was	still	reduced	with	late	CHE	exposure	compared	to	early	exposure	
(1.90	 	 2.00	 vs	 9.28	 	 3.56	 pg/	 ml,	 p<0.01),	 complementing	 the	 ELISpot	









We	hypothesised	 that	 the	 reduced	BCG‐induced	 IFN‐	 responses	with	 late	CHE	
exposure	may	be	 related	 to	enhanced	 induction	of	Tregs,	 relative	 to	early	CHE	
exposure.	 Thus,	 the	 proportions	 of	 FoxP3+,	 CD25+FoxP3+,	 CD25+GITRhiFoxP3+	
and	CD25+FR4hiFoxP3+	CD4+	 cells	 in	 spleens	of	vaccinated	mice	after	CHE	 lung	
exposure	 were	 determined	 by	 flow	 cytometry.	 However,	 no	 significant	
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differences	in	any	of	these	Treg	populations	were	found	between	early	and	late	
CHE	 exposed	 mice.	 There	 were	 significantly	 higher	 CD25+GITRhiFoxP3+	 and	




6.3.4	Post‐vaccination	 late	CHE	exposure	 increased	 systemic	BCG‐specific	
IFN‐	responses	upon	secondary	BCG	challenge		
Whether	CHE	altered	recall	responses	to	BCG	in	vivo	was	explored	next,	together	




higher	splenic	 IFN‐	 response	was	observed	 in	previously	BCG‐vaccinated	 than	
in	unvaccinated	mice	(Fig.	6.2B).	Early	CHE	exposure	did	not	significantly	alter	
this	 response,	 relative	 to	 unexposed	 mice	 (Fig.	 6.2B).	 However,	 late	 CHE	
exposure	led	to	significantly	higher	frequencies	of	IFN‐	producing	cells,	relative	
to	 unexposed	mice	 (Fig	 6.2C).	 Thus,	 the	 early	 BCG	 priming	 can	 be	 boosted	 by	
late,	 but	 not	 early,	 CHE	 exposure	 post‐vaccination,	 leading	 to	 an	 enhanced	
secondary	BCG	recall	 response.	Notably,	 the	naïve	mice,	 and	 indeed,	 almost	all	
treatment	groups,	showed	stronger	IFN‐	responses	to	BCG	challenge	at	the	later	
time	 point	 (comparing	 same	 treatment	 groups	 pairwise	 p<0.05	 for	 all	 groups	
except	BCG‐vaccinated	and	challenged	mice	(p=0.14),	Fig	6.2B	vs	6.2C).	This	may	
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be	 because	 the	 older	mice	with	more	mature	 immune	 systems	mounted	more	
robust	responses	to	both	CHE	and	BCG	challenge.		
	







the	 early	 time	 point,	 relative	 to	 unvaccinated	 but	 challenged	mice	 (Fig.	 6.3C).	
Therefore,	BCG	vaccination	 increased	 the	Treg	 response	upon	 subsequent	BCG	
challenge.	 Early	 CHE	 exposure	 did	 not	 significantly	 alter	 proportions	 of	 Tregs	
(Fig.	 6.3A,	 6.3C).	 In	 contrast,	 in	 mice	 exposed	 late	 to	 CHE,	 relative	 to	 mice	
without	CHE	exposure,	 systemic	 frequency	of	CD4+	 cells	 expressing	both	CD25	
and	 GITRhi	 were	 elevated	 post‐BCG	 challenge	 (Fig.	 6.3D).	 There	was	 a	 smaller	
increase	 in	 CD4+CD25+FoxP3+	 cells	 (Fig	 6.3B,	 significant	 by	 t‐test	 comparison	
with	non‐exposed	mice,	but	not	by	ANOVA).	This	could	mean	that	only	later	CHE	
exposure	post‐vaccination	results	in	Treg	induction,	or	perhaps	murine	age	and	
maturity	 of	 the	 immune	 system	 have	 an	 influence	 on	 Treg	 induction.	 The	








(A)	 Post‐BCG	 challenge	 scheme	 for	 vaccination	 and	 CHE	 exposure,	 at	 early	 and	
late	 time	 points.	 Frequency	 of	 BCG‐specific	 IFN‐	 producing	 splenocytes	 three	
weeks	post‐BCG	challenge	from	(B)	early	or	(C)	late	CHE	i.t.	exposure	as	shown	in	


























mice	 (Fig.	 6.4A,	 6.4C).	 Late	 CHE	 exposure	 also	 resulted	 in	 no	 significant	
difference	 in	 the	 same	 two	 groups	 (Fig.	 6.4B,	 6.4D).	 	 Frequencies	 of	 these	
memory	cells	were	therefore	unaffected	by	CHE	exposure,	despite	the	increased	
frequency	 of	 Tregs	 with	 late	 exposure.	 This	 implies	 that	 the	 Tregs	 do	 not	










infection	 i.t.	 (as	 in	Fig.	 6.2A),	were	 stimulated	with	PMA/ionomycin	 for	16‐18h	








Lung	 infiltration	 of	 immune	 cells	 after	 BCG	 challenge	 was	 measured	 by	 flow	
cytometry	 to	 determine	 whether	 post‐vaccination	 CHE	 exposure	 affects	 local	
responses	to	BCG	lung	challenge.		At	the	early	time‐point,	compared	to	untreated	
mice,	 BCG	 challenge	 of	 naïve	 mice	 did	 not	 increase	 any	 of	 the	 leucocyte	
populations	 measured	 (Fig.	 6.5A).	 However,	 BCG‐vaccinated	 mice	 had	 a	
significant	 increase	 in	 numbers	 of	 activated	 macrophages	 (F4/80+CD11b+)	
recruited	to	the	lungs	(p<0.01,	Fig.	6.5A)	following	lung	challenge,	compared	to	




lung	 populations	 of	 macrophages	 (F4/80+),	 activated	 macrophages	
(F4/80+CD11b+)	 and	 T	 cells	 (CD3+),	 but	 not	 neutrophils	 (Gr1+),	 in	 BCG‐
vaccinated	 relative	 to	 naïve	mice	 (Fig.	 6.5B).	 	 This	 indicated	 that	 BCG	 priming	
enhanced	 inflammatory	 cell	 recruitment	 upon	 secondary	 exposure.	 With	
intervening	 CHE	 exposure,	 there	 was	 substantially	 reduced	 recruitment	 of	
macrophages,	activated	macrophages	and	T	cells	to	the	lungs	(p<0.01,	Fig.	6.5B),	









CD11b	 (together	with	 F4/80	 =	 activated	macrophages	 )	 analysed	 by	 flow	 cytometry	were	 normalised	 to	 volume	 analysed	 and	 tissue	








reduced	 the	 numbers,	 and	 possibly	 also	 the	 activation	 status	 (proportion	 of	
F4/80+CD11b+	cells),	of	lung	immune	cells	locally	post‐BCG	challenge.		To	further	
investigate	 the	 factors	 responsible	 for	 this	 observation,	 various	 inflammatory	
mediators	 in	 lung	 tissue	were	measured	at	 the	 late	 time	point.	Upon	BCG	 lung	
challenge,	 BCG‐vaccinated	mice	 had	 significantly	 elevated	 levels	 of	 IL‐4,	 IL‐17,	
MIP‐1,	MIP‐1,	RANTES,	 IL‐1,	 and	 IL‐12/23p40	 in	 the	 lungs,	 compared	with	
naive	mice	 (p<0.05,	 Fig.	 6.6).	 In	 vaccinated	mice,	 CHE	 exposure	 between	 BCG	
priming	and	challenge	significantly	reduced	the	post‐challenge	levels	of	MIP‐1,	
MIP‐1,	RANTES,	IL‐12/23p40	(Fig.	6.6).		The	other	three	cytokines	(IL‐4,	IL‐17,	
and	 IL‐1,)	 were	 also	 reduced,	 but	 did	 not	 reach	 statistical	 significance.	
Interestingly,	post‐challenge	IL‐10	 levels	were	also	decreased	by	CHE	exposure	
(p<0.05,	 Fig.	 6.6),	 indicating	 that	 the	 suppression	 of	 immune	 cell	 recruitment	
was	not	due	to	IL‐10.	Taken	together,	the	heightened	immune	cell	recruitment	as	
well	 as	 lung	 tissue	 cytokine	 and	 chemokine	 levels	 upon	 BCG	 lung	 challenge	
suggest	 an	 enhanced	 local	 innate	 and	 adaptive	 immune	 response	 in	 BCG‐
vaccinated	relative	 to	naïve	mice.	 	CHE	exposure	 late	post‐vaccination	reduced	













































literature	 suggests	 that	Treg	 induction	 should	be	 favored	 in	 the	gut	 (Coombes,	
2007),	 but	 no	 systemic	 IFN‐	 changes	 (Fig	 6.1B,	 C)	 or	 upregulation	 of	 splenic	
nTregs	(not	shown)	was	noted	when	post‐vaccination	CHE	exposure	was	given	
orally.	 The	 findings	 in	 this	 study	 concur	 with	 others	 showing	 that	 BCG	
vaccination	 followed	 by	 repeated	 oral	M.	 avium	 by	 gavage	 does	 not	 alter	Mtb	
antigen‐specific	 IFN‐	upon	subsequent	Mtb	aerosol	challenge	(Flaherty,	2006).	
Perhaps	 the	 strong	 systemic	 pro‐inflammatory	 responses	 induced	 by	 BCG	
priming	 exceed	 a	 small	 tolerogenic	 effect	 of	 subsequent	 oral	 Env	 exposure.	
Different	extents	of	Env	persistence	in	host	organs	are	also	likely	to	affect	extent	
of	 host	 immune	 stimulation	 (Brandt,	 2002;	 Demangel,	 2005).	 It	 has	 been	
suggested	 that	 sequestration	 of	 protective	 T	 cells	 to	 brachial	 lymph	 nodes	 or	
immune	exhaustion	due	 to	persistent	M.	avium	 colonisation	of	 the	 lungs	 (after	
oral	 gavage)	 may	 account	 for	 subsequent	 poor	 Mtb	 control	 (Flaherty,	 2006).	
Since	 CHE	 is	 rapidly	 cleared	 from	 the	 lungs	within	 two	weeks	 even	with	 high	







many	 antigens	 shared	 between	 CHE	 and	 BCG	 can	 be	 expected.	 Therefore,	 the	
BCG‐specific	 IFN‐	 response	 was	 predictably	 increased	 with	 CHE	 boosting	 of	
BCG‐vaccination	 primed	 immunity	 (Fig	 6.1B),	 and	 also	 with	 CHE	 priming	 just	
before	BCG	challenge	(Fig	6.2C).	Notably,	the	booster	effect	was	diminished	with	
elapse	of	 time	between	priming	and	boosting	(Fig	6.1C),	which	supports	cross‐




may	 specifically	 or	 non‐specifically	 downregulate	 the	 BCG‐specific	 IFN‐	
response.	 The	 literature	 contains	 many	 examples	 of	 Treg	 activity	 following	
infection	 with	 Env	 (Bermudez	 and	 Champsi,	 1993;	 Zuany‐Amorim,	 2002b;	
Hernandez‐Pando,	 2008;	 Mendoza‐Coronel,	 2010).	 There	 is	 evidence	 that	
existing	 inflammatory	 lung	 responses	 can	 be	 reduced	 non‐specifically	 by	 Env‐
induced	 Tregs	 (Zuany‐Amorim,	 2002b).	 	 However,	 the	 role	 of	 Tregs	 present	
before	 BCG	 vaccination	 (presumed	 to	 be	 Env‐induced)	 in	 suppressing	 BCG‐
induced	 IFN‐	 levels	 is	 uncertain	 because	 CD4+CD25+FoxP3+	 Treg	 frequencies	
and	IL‐10	production	before	BCG	vaccination	do	not	correlate	with	IFN‐	 levels	
post‐vaccination	 in	human	 infants	(Burl,	2010).	Likewise,	post‐BCG	vaccination	
i.t.	 CHE	 exposure	 in	 this	 study	 led	 to	 increased	 Tregs	 upon	 subsequent	 BCG	
challenge,	but	this	failed	to	suppress	the	BCG‐induced	IFN‐	response	(Fig	6.2B,	
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6.4.3	 Contrast	with	M.	 vaccae	model	 of	 IL‐10	mediated	 lung	 suppressive	
effects		
Good	evidence	 for	suppression	of	existing	 inflammation	by	Env	comes	 from	an	
ovalbumin‐induced	murine	allergy	model.	Oral	or	subcutaneous	treatment	with	
dead	 M.	 vaccae	 significantly	 reduces	 pulmonary	 inflammatory	 infiltrates,	
through	 increasing	 lung	 IL‐10	 production	 (Hunt,	 2005).	 In	 this	 model,	 the	M.	
vaccae	 induced	 Treg	 response	 is	 non‐specific,	 affecting	 lung	 inflammation	
triggered	 by	 allergens	 distinct	 from	 Mycobacterium	 antigens.	 However,	 the	
suppression	occurs	primarily	at	the	inflammed	(lung)	site	–	the	effect	on	splenic	
IL‐10	and	IFN‐	 is	minimal.	 In	 this	study,	CHE	clearly	 induces	suppressive	 lung	
effects	 via	 different	 mechanisms	 from	 M.	 vaccae,	 as	 lung	 IL‐10	 levels	 were	
actually	decreased	in	i.t.	CHE	exposed	mice	after	BCG	challenge	(Fig.	6.6),	so	IL‐
10	 cannot	 account	 for	 the	 suppression	 in	 inflammatory	 cell	 recruitment.	 The	







The	 systemic	 increase	 in	 CD25+GITRhi	 cells	 (and	 CD4+CD25+FoxP3+	 cells	 to	 a	
lesser	extent)	amongst	the	CD4+	lymphocytes	(Fig	6.3B,	D)	suggests	an	increase	
of	 nTregs,	 rather	 than	 adaptive	 Tregs,	when	 CHE	was	 given	 post‐BCG.	 Indeed,	
BCG	 vaccination	 alone	 induced	 CD4+CD25+GITRhi	 nTregs	 (Fig.	 6.3C).	 Notably,	
with	CHE	sensitisation	alone,	the	frequency	of	CD4+CD25+FoxP3+	nTregs	and	IL‐
10	producing	cells	were	unremarkable	(Chapters	4	and	5).	Therefore,	it	appears	
that	 nTregs	 are	 not	 primarily	 induced	 with	 CHE	 exposure,	 but	 rather,	 nTregs	





the	opposite	 effect	 of	 retarding	 the	 recruitment	 (Shafiani,	 2010).	Mtb	 infection	
does	 not	 cause	 non‐specific	 proliferation	 of	 all	 CD4+FoxP3+	 cells,	 but	 leads	 to	
Mtb‐specific	Tregs	being	preferentially	expanded	from	a	pre‐existing	repertoire	
of	 nTregs	 in	 the	murine	 host	 (Shafiani,	 2010).	 Such	 specific	 Tregs	 can	 restrict	
expansion	of	 effector	T	 cells	whose	epitope	 specificity	differs	 from	 the	epitope	
recognised	 by	 the	 Tregs.	 The	 authors	 suggest	 that	 this	 may	 be	 due	 to	 Mtb‐
specific	 Tregs	 recognising	 particular	 immunodominant	 antigens	 presented	 on	
DCs,	 leading	 to	 interactions	 which	 impair	 the	 DCs’	 co‐stimulatory	 functions	
(Shafiani,	2010).	By	extension,	this	mechanism	could	also	account	for	how	BCG‐
primed	 Tregs	 could	 be	 re‐activated	 and	 expanded	 by	 cross‐reactive	 antigens	
upon	 subsequent	 CHE	 exposures.	 Higher	 frequencies	 of	 expanded	
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Mycobacterium‐specific	 Tregs	 in	 the	 lungs,	 following	 repeated	 lung	 CHE	
exposures,	 would	 explain	 the	 poorer	 inflammatory	 cell	 recruitment	 to	
subsequent	lung	infection	by	BCG	(or	Mtb),	as	noted	in	this	study	(Fig	6.5).	There	
is	increasing	support	for	the	notion	that	the	rate	at	which	effector	T	cells	reach	
the	 lung,	 rather	 than	 the	 level	 of	 systemic	 Mycobacterium‐specific	 IFN‐	
response,	is	the	critical	feature	of	protective	immunity	in	Mtb	infection	(Cooper,	
2009).	Likewise,	higher	levels	of	systemic	BCG‐specific	cells	in	CHE	exposed	mice	
may	 not	 prevent	 the	 undermining	 of	 lymphocyte	 recruitment	 to	 the	 BCG‐
challenged	 lungs	 caused	 by	 the	 CHE‐expanded	 Tregs.	 This	 explains	 the	




6.4.5	 Differential	 Treg	 responses	 primed	 with	 pre‐	 versus	 post‐BCG	
vaccination	CHE	exposure		
The	 fact	 that	BCG	vaccination	alone	 increases	nTregs	 (but	not	 IL‐10)	 in	 infants	
after	neonatal	vaccination	(Burl,	2010)	may	explain	why	a	BCG‐prime‐CHE‐boost	
model	 in	 this	 study	 led	 to	 expanded	 nTregs	 upon	 BCG	 challenge,	 rather	 than	
increased	IL‐10	production.	Conversely,	when	CHE	sensitisation	occurred	before	
BCG	challenge,	IL‐10	was	increased	(Chapter	4,	Fig	4.2B	and	Chapter	5,	Fig	5.7)	
but	 the	 increase	 in	 frequency	 of	 CD4+CD25+	 nTregs	 was	 relatively	 modest	
(Chapter	 4,	 Fig	 4.3A	 and	 Chapter	 5,	 Fig	 5.8),	 consistent	 with	 a	 predominantly	
adaptive	 Treg	 response.	 	 This	 may	 be	 because	 BCG	 vaccination	 provides	 a	
stronger	 initial	 priming	 stimulus	 for	 Th1	 mediated	 inflammation	 and	
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concomitant	 expansion	 of	 Mycobacterium‐specific	 nTregs,	 that	 is	 boosted	 by	
subsequent	 repeated	 CHE	 exposure.	 In	 contrast,	 CHE	 priming	 –	 being	 a	
commonly	 encountered	 Env	 tolerated	 by	 the	 immune	 system	 –	 leads	 to	 less	
inflammation	and	less	nTreg	expansion,	but	repeated	low	dose	antigen	exposure	
can	 induce	 peripheral	 conversion	 of	 CD4+CD25‐	 effector	 cells	 to	 FoxP3+	 Tregs	
(Kretschmer,	 2005).	 This	 phenomenon	 was	 illustrated	 in	 Chapter	 4,	 Fig	 4.4E	
with	CHE‐sensitised	mice,	and	CD4+CD25‐FoxP3+	cells	were	the	predominant	IL‐
10	 producing	 adaptive	 Tregs	 after	 BCG	 vaccination	 of	 CHE‐sensitised	 mice	
(Chapter	 5).	 The	 impact	 of	 CD4+CD25+	 nTregs	 appeared	 to	 be	 in	 suppressing	
leucocyte	recruitment	to	the	Mycobacterium	 infected	lung	(shown	in	Chapter	4,	







several	 mechanisms	 by	 CHE	 exposure,	 even	 when	 the	 exposure	 occurs	 after	
vaccination.	 In	humans,	Env	exposure	 is	 inevitable	 throughout	 life	 (Vaerewijck,	
2005),	and	cumulative	Env	exposure	could	form	part	of	the	explanation	for	the	
waning	of	BCG‐induced	protection	(Comstock,	1976;	Sterne,	1998).	The	findings	




vaccination	 may	 be	 primarily	 through	 reducing	 local	 lung	 inflammatory	 cell	
recruitment	 early	 in	 TB	 infection,	 rather	 than	 through	 suppressing	 systemic	
BCG‐specific	cytokine	or	memory	responses.	It	could	be	inferred	from	Shafiani’s	
work	(Shafiani,	2010)	that	an	assay	of	Mycobacterium‐specific	nTregs	that	can	be	









discovered	 for	 the	 immunomodulatory	 effects	 of	 CHE	 on	 BCG	 can	be	 tested	 in	
new	 vaccines	 to	 check	 if	 similar	 pitfalls	 exist.	 Two	 novel	 mechanisms	 were	
described	 here.	 	 First,	 CHE	 sensitisation	 induced	 CD4+	 mediated	 cytotoxicity	
against	BCG	infected	cells	that	limited	the	replication	of	BCG,	and	was	dependent	
on	IFN‐,	perforin	and	FasL.	Second,	CHE	sensitisation	induced	various	types	of	
Tregs	 upon	BCG	 vaccination,	 including	 IL‐10	 producing	 iTregs	 and	 CD4+CD25+	
nTregs,	 that	 suppressed	 systemic	 BCG‐specific	 memory	 responses	 and	 local	




An	 important	 finding	 was	 that	 CD4+CD25+	 nTregs	 from	 CHE‐sensitised	 mice,	
though	unremarkable	in	frequency,	proved	to	be	responsible	for	reducing	early	
lung	 lymphocyte	 recruitment	 to	 local	Mycobacterium	 infection,	which	has	been	
described	as	 the	critical	 factor	determining	outcome	of	Mtb	 infections	 (Cooper,	
2009).	CHE	exposure	after	BCG	vaccination	likewise	led	to	expansion	of	nTregs	
with	 similar	 suppression	 of	 cellular	 recruitment	 without	 systemic	 IFN‐γ	
suppression.	This	study	is	also	the	first	to	show	a	mechanism	that	explains	how	
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Env	 exposures	 can	 modulate	 an	 existing	 BCG	 vaccine	 response,	 which	 has	
relevance	 to	 neonatal	 vaccination	 programmes.	 Adaptive	 (inducible)	 Tregs	
producing	 IL‐10	were	not	 induced	when	BCG	vaccination	occurred	before	CHE	









IL‐10	 producing	 iTregs	may	 be	 useful	 indicators	 of	 vaccine‐induced	 protective	
outcomes,	rather	than	the	current	tests	of	IFN‐γ	producing	cells.		
	
Both	 live	 and	 dead	 CHE	 gave	 similar	 responses,	 but	 memory	 responses	 after	
transient	CHE	lung	colonisation	led	to	a	build‐up	of	inflammatory	and	regulatory	
T	 cells	 for	weeks.	 Indeed,	 expansion	of	memory	 cells	 (nTregs,	 cytotoxic	T	 cells	
and	BCG‐specific	IFN‐γ	producing	cells)	occurs	with	both	CHE‐prime‐BCG	boost	
and	 BCG‐prime‐CHE‐boost	 models,	 but	 to	 different	 extents.	 The	 priming	














negatively	 affect	 the	 vaccine’s	 protective	 capability,	 strategies	 to	 block	 such	
responses	 in	 conjunction	 with	 the	 administration	 of	 the	 vaccine	 has	 to	 be	
considered.	This	work	has	additionally	uncovered	a	novel	reason	 for	why	even	
neonatal	 BCG	 vaccination	 fails	 to	 provide	 long‐lasting	 effects	 against	 adult	






Although	 functional	 suppressive	 cells,	 which	 could	 inhibit	 BCG‐induced	
responses,	were	 observed	 in	 CHE‐sensitised	mice,	 this	 study	 did	 not	 ascertain	
the	 antigen	 specificity	 of	 these	 cells.	 It	 remains	 to	 be	 determined	whether	 the	
suppressive	effects	observed	in	this	model	resulted	from	bystander	suppression,	
whereby	 active	 Tregs	 exerted	 their	 effects	 on	 surrounding	 cells	 regardless	 of	
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antigen	 specificity,	 or	 from	 antigen‐specific	 Tregs	 recognising	 antigens	 shared	
between	CHE	and	BCG.	One	possible	way	to	 investigate	this	 is	to	use	RAG	gene	
knock‐out	 mice,	 which	 are	 devoid	 of	 functional	 T	 and	 B	 cells,	 a	 model	 used	
effectively	 in	 previous	 Treg	 studies	 (Kursar,	 2007).	 These	 mice	 can	 be	
reconstituted	with	various	phenotypes	of	Tregs	from	CHE	mice	and	functional	T	




In	 CHE‐exposed	 mice	 vaccinated	 with	 BCG,	 IL‐10	 secreting	 CD4+	 cells	 were	
elevated	in	frequency.	Others	in	our	laboratory	have	ascertained	that	removal	of	
these	 cells	 in	 vivo	 reverses	 the	 suppression	 of	 BCG	 induced	 IFN‐γ	 responses	
(data	 not	 shown).	 Both	murine	 (Kursar,	 2007)	 and	human	 (Burl,	 2010;	Marin,	
2010)	 studies	 suggest	 that	 IL‐10	 is	 not	 correlated	 with	 Treg‐mediated	
suppression	 of	 BCG	 or	 TB	 responses.	 However,	 most	 of	 those	 studies	 were	
primarily	looking	at	CD4+CD25+	Tregs,	rather	than	iTregs	that	are	more	likely	to	
produce	 IL‐10.	An	 investigation	of	 the	effects	on	BCG	responses	upon	adoptive	
transfer	 of	 the	 IL‐10	 secreting	 iTregs	 described	 in	 CHE‐sensitised	mice	 in	 this	
study,	 into	 BCG‐vaccinated	 mice	 would	 confirm	 their	 ability	 to	 suppress	 BCG	






(Forbes,	 2008),	 as	 well	 as	 Th17	 cells	 that	 produce	 IL‐23	 and	 IL‐17	 (Khader,	
2007;	Chen,	2010),	have	been	suggested	to	be	 important	 for	protection	against	
TB	 infection.	 It	would	therefore	be	 interesting	 to	study	whether	Env‐sensitised	
mice	are	altered	in	their	production	of	such	cells.	Furthermore,	Marin	et	al	show	
that	 in	vitro	Treg	depletion	before	 antigen	 stimulation	of	 cells	 from	active	 and	
latent	 TB	 patients	 increases	 the	 frequency	 of	 IFN‐	 secreting	 but	 not	 IL‐17	
secreting	 cells	 (Marin,	2010).	Hence,	 future	studies	 should	 investigate	whether	
Env‐induced	Tregs	 found	 in	 this	study	 influences	BCG‐mediated	responses	 in	a	
similar	way	–	affecting	the	protective	Th1	responses	but	not	the	IL‐17	responses.	
It	would	also	be	interesting	to	explore	whether	these	changes	to	Th1	and	Th17	




Since	 only	 one	 species	 of	 Env	 (CHE)	 was	 studied	 here,	 the	 findings	 may	 only	
represent	a	proportion	of	the	Env	interference	on	human	immunity.	The	addition	
of	 other	 Env	 species	 may	 compound	 the	 influences	 of	 CHE	 on	 BCG‐mediated	
responses,	and	this	should	be	explored.	Brandt	demonstrated	that	in	mice,	prior	
to	BCG	vaccination,	exposure	to	a	combination	of	M.	avium,	M.	fortuitum	and	M.	




vaccination	 in	 mice	 (Demangel,	 2005).	 Demangel	 opined	 that	 slow	 growing	
mycobacteria	(closer	genetic	relations	to	BCG)	may	be	more	likely	to	affect	BCG	
responses,	 but	 only	 studied	 a	 limited	 spectrum	 of	 cellular	 responses	 to	 BCG.	
Further	 studies	 should	 explore	 whether	 the	 effects	 of	 CHE	 exposure	 on	
cytotoxicity	 and	 Tregs	 that	 were	 uncovered	 in	 the	 present	 work	 are	 similarly	





A	 major	 limitation	 of	 the	 present	 work	 is	 that	 the	 CHE‐induced	 suppressive	
effects	documented	were	not	directly	verified	 through	Mtb	challenge.	This	was	
not	possible	 in	 the	 time‐span	of	 this	work	due	 to	unavailability	 of	 appropriate	
containment	 facilities.	 Now	 that	 various	 mechanistic	 leads	 have	 been	
established,	 removing/neutralising	 the	 suppressive	 pathways	 from	 CHE‐
sensitised	 mice	 and/or	 adoptive	 transfer	 of	 the	 relevant	 suppressive	 cells,	
followed	 by	 Mtb	 challenge	 would	 be	 a	 more	 rigorous	 model	 for	 testing	 the	
relevance	 of	 these	 mechanisms.	 For	 example,	 antibody‐mediated	 depletion	 of	
CD4+CD25+	cells	(Jaron,	2008)	or	IL‐10	secreting	cells	from	CHE‐sensitised	mice	








BCG‐mediated	 responses.	However,	 the	 relevance	of	 our	 observations	depends	
on	 having	 studied	 the	 appropriate	 BCG‐induced	 responses	 that	 correlate	 with	
BCG‐attributable	protection	 against	TB.	 The	 concern	 is	 that	 Env	 exposure	may	
affect	many	aspects	of	BCG‐induced	cellular	immunity,	but	these	may	not	directly	
affect	BCG‐induced	protection	against	Mtb.	For	a	long	time,	vaccine‐induced	IFN‐
γ	 responses	 were	 accepted	 as	 the	 main	 surrogate	 marker	 for	 protection	 in	
vaccine	studies	(Flynn,	2004;	Scriba,	2010),	but	currently	this	 is	 in	some	doubt	




global	 research	 efforts.	 A	 recent	 large‐scale	 neonatal	 BCG	 study	 exploring	
immune	 outcomes	 of	 BCG	 vaccination,	 in	 relation	 to	 pre‐BCG	 vaccination	
immune	 parameters,	 such	 as	 T	 cell	 frequency	 and	 cytokine	 expression,	 found	
that	 none	 of	 these	 were	 correlated	 with	 risk	 of	 TB	 infection	 (Kagina,	 2010).	
Therefore,	 considerations	 on	 future	 work	 regarding	 what	 effects	 Env	 have	 on	
BCG	 responses	 must	 be	 taken	 together	 with	 knowing	 what	 BCG‐induced	
parameters,	 if	 suppressed,	 have	 the	 greatest	 impact	 on	 BCG‐conferred	
protection.	 This	 means	 that	 we	 must	 join	 in	 the	 global	 effect	 to	 uncover	 the	
elusive	 immune	 correlates	 of	 BCG	 protection	 or	 BCG	 failure.	 Based	 on	 the	
findings	in	this	study,	it	would	be	reasonable	to	start	with	a	prospective	study	in	
human	 infants	 given	 neonatal	 BCG,	 testing	whether	 post‐vaccination	 assays	 of	
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broth	 50%	 20%	 OADC	
water	 powder	 Glycerol	 Tween	80 	









broth	 50%	 20%	 OADC	
water	 powder	 Glycerol	 Tween	80 	












50	ml	 50	ml	 25	mg	 1	g	 1g	
	
All	ingredients	were	added	at	room	temperature	and	mixed	by	stirring.		Medium	
was	sterilised	by	filter	through	a	0.22	mm	filter.		
	
Red	blood	cell	lysis	solution	(0.17	M	NH4Cl)	
	
Volume	 Nanopure	
Ammonim	
chloride	
water	 (NH4Cl)	
10	ml	 10	ml	 90	mg	
	
All	 ingredients	were	added	at	room	temperature	and	mixed	by	stirring.	 	Adjust	
pH	to	7.3	and	autoclave	at	121	C	for	15	min.	Solution	was	stored	at	4	C	before	
use.	
	
